```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 20:38:24 ON 31 AUG 2006
FILE 'CAPLUS' ENTERED AT 20:38:24 ON 31 AUG 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   401.06     976.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -25.50     -30.75

=> s us2005261298/pn
L32           2 US2005261298/PN

=> s 143:472565/dn
L33           1 143:472565/DN

=> d rn

L33  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
RN   60-92-4
RN   127464-60-2
RN   40622-01-3P
RN   66085-59-4P
RN   306764-68-1P
RN   312501-62-5P
RN   331945-22-3P
RN   353771-45-6P
RN   91-56-5
RN   108-31-6
RN   108-38-3
RN   119-80-2
RN   619-05-6
RN   1226-42-2
RN   4506-71-2
RN   5242-26-2
RN   64900-65-8
RN   82799-44-8
RN   569656-05-9
RN   569656-06-0
RN   7741-54-0P
RN   76293-13-5P
RN   569656-29-7P
RN   7440-70-2


=> select l33
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E210 THROUGH E233 ASSIGNED
```

```
=> d sel
E1              1       108-31-6/BI
E2              1       108-38-3/BI
E3              1       119-80-2/BI
E4              1       1226-42-2/BI
E5              1       127464-60-2/BI
E6              1       306764-68-1/BI
E7              1       312501-62-5/BI
E8              1       331945-22-3/BI
E9              1       353771-45-6/BI
E10             1       40622-01-3/BI
E11             1       4506-71-2/BI
E12             1       5242-26-2/BI
E13             1       569656-05-9/BI
E14             1       569656-06-0/BI
E15             1       569656-29-7/BI
E16             1       60-92-4/BI
E17             1       619-05-6/BI
E18             1       64900-65-8/BI
E19             1       66085-59-4/BI
E20             1       7440-70-2/BI
E21             1       76293-13-5/BI
E22             1       7741-54-0/BI
E23             1       82799-44-8/BI
E24             1       91-56-5/BI
E25             1       108-31-6/BI
E26             1       108-38-3/BI
E27             1       119-80-2/BI
E28             1       1226-42-2/BI
E29             1       127464-60-2/BI
E30             1       306764-68-1/BI
E31             1       312501-62-5/BI
E32             1       331945-22-3/BI
E33             1       353771-45-6/BI
E34             1       40622-01-3/BI
E35             1       4506-71-2/BI
E36             1       5242-26-2/BI
E37             1       569656-05-9/BI
E38             1       569656-06-0/BI
E39             1       569656-29-7/BI
E40             1       60-92-4/BI
E41             1       619-05-6/BI
E42             1       64900-65-8/BI
E43             1       66085-59-4/BI
E44             1       7440-70-2/BI
E45             1       76293-13-5/BI
E46             1       7741-54-0/BI
E47             1       82799-44-8/BI
E48             1       91-56-5/BI
E49             1       100-65-2/BI
E50             1       107235-67-6/BI
E51             1       108-31-6/BI
E52             1       108-38-3/BI
E53             1       112612-58-5/BI
E54             1       113054-02-7/BI
E55             1       120-72-9/BI
E56             1       1226-42-2/BI
E57             1       123-11-5/BI
E58             1       127464-60-2/BI
E59             1       13100-05-5/BI
E60             1       13380-67-1/BI
E61             1       136382-28-0/BI
E62             1       140-75-0/BI
```

E63	1	1468-83-3/BI
E64	1	1476-23-9/BI
E65	1	149246-80-0/BI
E66	1	149246-86-6/BI
E67	1	1572-10-7/BI
E68	1	171286-07-0/BI
E69	1	173275-26-8/BI
E70	1	177360-28-0/BI
E71	1	182762-25-0/BI
E72	1	19541-95-8/BI
E73	1	208519-10-2/BI
E74	1	208519-15-7/BI
E75	1	218763-60-1/BI
E76	1	23448-86-4/BI
E77	1	23821-37-6/BI
E78	1	259476-69-2/BI
E79	1	262400-57-7/BI
E80	1	2642-63-9/BI
E81	1	26993-30-6/BI
E82	1	292076-38-1/BI
E83	1	302-01-2/BI
E84	1	304650-31-5/BI
E85	1	306764-68-1/BI
E86	1	309282-30-2/BI
E87	1	311773-65-6/BI
E88	1	311799-07-2/BI
E89	1	312501-62-5/BI
E90	1	312519-16-7/BI
E91	1	312594-43-7/BI
E92	1	321679-76-9/BI
E93	1	322662-05-5/BI
E94	1	327167-87-3/BI
E95	1	329069-72-9/BI
E96	1	329350-38-1/BI
E97	1	330630-42-7/BI
E98	1	331274-84-1/BI
E99	1	331945-22-3/BI
E100	1	332161-39-4/BI
E101	1	334498-72-5/BI
E102	1	337349-59-4/BI
E103	1	337469-26-8/BI
E104	1	337498-14-3/BI
E105	1	342384-25-2/BI
E106	1	346699-98-7/BI
E107	1	353253-35-7/BI
E108	1	353273-74-2/BI
E109	1	353463-50-0/BI
E110	1	353771-45-6/BI
E111	1	353793-15-4/BI
E112	1	355000-90-7/BI
E113	1	363-58-6/BI
E114	1	364051-15-0/BI
E115	1	36817-57-9/BI
E116	1	372-31-6/BI
E117	1	383164-60-1/BI
E118	1	384729-36-6/BI
E119	1	385223-15-4/BI
E120	1	389079-78-1/BI
E121	1	390105-18-7/BI
E122	1	390174-36-4/BI
E123	1	390523-03-2/BI
E124	1	39151-19-4/BI
E125	1	392101-34-7/BI

E126	1	400064-03-1/BI
E127	1	406-00-8/BI
E128	1	40622-01-3/BI
E129	1	43071-45-0/BI
E130	1	434-75-3/BI
E131	1	4506-71-2/BI
E132	1	473390-98-6/BI
E133	1	49843-94-9/BI
E134	1	50-30-6/BI
E135	1	50-45-3/BI
E136	1	502132-61-8/BI
E137	1	5242-26-2/BI
E138	1	533-18-6/BI
E139	1	5351-85-9/BI
E140	1	5351-91-7/BI
E141	1	5467-70-9/BI
E142	1	556-90-1/BI
E143	1	569655-94-3/BI
E144	1	569655-95-4/BI
E145	1	569655-96-5/BI
E146	1	569655-97-6/BI
E147	1	569655-98-7/BI
E148	1	569655-99-8/BI
E149	1	569656-00-4/BI
E150	1	569656-01-5/BI
E151	1	569656-02-6/BI
E152	1	569656-03-7/BI
E153	1	569656-04-8/BI
E154	1	569656-05-9/BI
E155	1	569656-06-0/BI
E156	1	569656-07-1/BI
E157	1	569656-08-2/BI
E158	1	569656-09-3/BI
E159	1	569656-10-6/BI
E160	1	569656-11-7/BI
E161	1	569656-12-8/BI
E162	1	569656-13-9/BI
E163	1	569656-14-0/BI
E164	1	569656-15-1/BI
E165	1	569656-16-2/BI
E166	1	569656-17-3/BI
E167	1	569656-18-4/BI
E168	1	569656-19-5/BI
E169	1	569656-20-8/BI
E170	1	569656-21-9/BI
E171	1	569656-22-0/BI
E172	1	569656-23-1/BI
E173	1	569656-24-2/BI
E174	1	569656-25-3/BI
E175	1	569656-26-4/BI
E176	1	569656-27-5/BI
E177	1	569656-28-6/BI
E178	1	569656-29-7/BI
E179	1	60-92-4/BI
E180	1	619-05-6/BI
E181	1	619-41-0/BI
E182	1	6292-74-6/BI
E183	1	64900-65-8/BI
E184	1	6629-60-3/BI
E185	1	70-11-1/BI
E186	1	72411-52-0/BI
E187	1	7420-34-0/BI
E188	1	7440-70-2/BI

```
E189          1     76293-13-5/BI
E190          1     7741-53-9/BI
E191          1     7741-54-0/BI
E192          1     79-19-6/BI
E193          1     82799-44-8/BI
E194          1     82799-45-9/BI
E195          1     829-20-9/BI
E196          1     83-38-5/BI
E197          1     86358-85-2/BI
E198          1     89570-85-4/BI
E199          1     90212-73-0/BI
E200          1     91-56-5/BI
E201          1     91912-53-7/BI
E202          1     93-17-4/BI
E203          1     93-55-0/BI
E204          1     94835-69-5/BI
E205          1     96799-03-0/BI
E206          1     96799-04-1/BI
E207          1     98-59-9/BI
E208          1     98-88-4/BI
E209          1     98-95-3/BI
E210          1     108-31-6/BI
E211          1     108-38-3/BI
E212          1     119-80-2/BI
E213          1     1226-42-2/BI
E214          1     127464-60-2/BI
E215          1     306764-68-1/BI
E216          1     312501-62-5/BI
E217          1     331945-22-3/BI
E218          1     353771-45-6/BI
E219          1     40622-01-3/BI
E220          1     4506-71-2/BI
E221          1     5242-26-2/BI
E222          1     569656-05-9/BI
E223          1     569656-06-0/BI
E224          1     569656-29-7/BI
E225          1     60-92-4/BI
E226          1     619-05-6/BI
E227          1     64900-65-8/BI
E228          1     66085-59-4/BI
E229          1     7440-70-2/BI
E230          1     76293-13-5/BI
E231          1     7741-54-0/BI
E232          1     82799-44-8/BI
E233          1     91-56-5/BI


=> e1-e233
E1-E233 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s e1-e233
         34885 108-31-6/BI
         17010 108-38-3/BI
           365 119-80-2/BI
           596 1226-42-2/BI
         15362 127464-60-2/BI
             3 306764-68-1/BI
             3 312501-62-5/BI
             3 331945-22-3/BI
             3 353771-45-6/BI
```

9	40622-01-3/BI
258	4506-71-2/BI
8	5242-26-2/BI
3	569656-05-9/BI
3	569656-06-0/BI
3	569656-29-7/BI
59933	60-92-4/BI
453	619-05-6/BI
104	64900-65-8/BI
2259	66085-59-4/BI
375926	7440-70-2/BI
73	76293-13-5/BI
4	7741-54-0/BI
620	82799-44-8/BI
2647	91-56-5/BI
34885	108-31-6/BI
17010	108-38-3/BI
365	119-80-2/BI
596	1226-42-2/BI
15362	127464-60-2/BI
3	306764-68-1/BI
3	312501-62-5/BI
3	331945-22-3/BI
3	353771-45-6/BI
9	40622-01-3/BI
258	4506-71-2/BI
8	5242-26-2/BI
3	569656-05-9/BI
3	569656-06-0/BI
3	569656-29-7/BI
59933	60-92-4/BI
453	619-05-6/BI
104	64900-65-8/BI
2259	66085-59-4/BI
375926	7440-70-2/BI
73	76293-13-5/BI
4	7741-54-0/BI
620	82799-44-8/BI
2647	91-56-5/BI
1137	100-65-2/BI
3	107235-67-6/BI
34885	108-31-6/BI
17010	108-38-3/BI
3	112612-58-5/BI
4	113054-02-7/BI
12946	120-72-9/BI
596	1226-42-2/BI
17537	123-11-5/BI
15362	127464-60-2/BI
25	13100-05-5/BI
148	13380-67-1/BI
5	136382-28-0/BI
778	140-75-0/BI
268	1468-83-3/BI
650	1476-23-9/BI
4	149246-80-0/BI
5	149246-86-6/BI
328	1572-10-7/BI
4	171286-07-0/BI
4	173275-26-8/BI
5	177360-28-0/BI
6	182762-25-0/BI
49	19541-95-8/BI

5	208519-10-2/BI
4	208519-15-7/BI
15	218763-60-1/BI
10	23448-86-4/BI
12	23821-37-6/BI
10	259476-69-2/BI
1	262400-57-7/BI
275	2642-63-9/BI
1187	26993-30-6/BI
2	292076-38-1/BI
23190	302-01-2/BI
2	304650-31-5/BI
3	306764-68-1/BI
4	309282-30-2/BI
2	311773-65-6/BI
2	311799-07-2/BI
3	312501-62-5/BI
2	312519-16-7/BI
2	312594-43-7/BI
1	321679-76-9/BI
3	322662-05-5/BI
1	327167-87-3/BI
3	329069-72-9/BI
2	329350-38-1/BI
3	330630-42-7/BI
1	331274-84-1/BI
3	331945-22-3/BI
2	332161-39-4/BI
2	334498-72-5/BI
2	337349-59-4/BI
2	337469-26-8/BI
2	337498-14-3/BI
1	342384-25-2/BI
2	346699-98-7/BI
3	353253-35-7/BI
3	353273-74-2/BI
2	353463-50-0/BI
3	353771-45-6/BI
3	353793-15-4/BI
2	355000-90-7/BI
55	363-58-6/BI
2	364051-15-0/BI
7	36817-57-9/BI
662	372-31-6/BI
3	383164-60-1/BI
5	384729-36-6/BI
18	385223-15-4/BI
2	389079-78-1/BI
5	390105-18-7/BI
4	390174-36-4/BI
5	390523-03-2/BI
132	39151-19-4/BI
4	392101-34-7/BI
2	400064-03-1/BI
28	406-00-8/BI
9	40622-01-3/BI
32	43071-45-0/BI
60	434-75-3/BI
258	4506-71-2/BI
3	473390-98-6/BI
8	49843-94-9/BI
350	50-30-6/BI
146	50-45-3/BI

2	502132-61-8/BI
8	5242-26-2/BI
190	533-18-6/BI
37	5351-85-9/BI
91	5351-91-7/BI
39	5467-70-9/BI
266	556-90-1/BI
2	569655-94-3/BI
2	569655-95-4/BI
2	569655-96-5/BI
1	569655-97-6/BI
2	569655-98-7/BI
3	569655-99-8/BI
3	569656-00-4/BI
2	569656-01-5/BI
2	569656-02-6/BI
2	569656-03-7/BI
1	569656-04-8/BI
3	569656-05-9/BI
3	569656-06-0/BI
1	569656-07-1/BI
2	569656-08-2/BI
1	569656-09-3/BI
2	569656-10-6/BI
2	569656-11-7/BI
2	569656-12-8/BI
2	569656-13-9/BI
2	569656-14-0/BI
2	569656-15-1/BI
1	569656-16-2/BI
2	569656-17-3/BI
2	569656-18-4/BI
2	569656-19-5/BI
2	569656-20-8/BI
2	569656-21-9/BI
1	569656-22-0/BI
3	569656-23-1/BI
3	569656-24-2/BI
2	569656-25-3/BI
3	569656-26-4/BI
3	569656-27-5/BI
2	569656-28-6/BI
3	569656-29-7/BI
59933	60-92-4/BI
453	619-05-6/BI
892	619-41-0/BI
11	6292-74-6/BI
104	64900-65-8/BI
74	6629-60-3/BI
5590	70-11-1/BI
7	72411-52-0/BI
6	7420-34-0/BI
375926	7440-70-2/BI
73	76293-13-5/BI
6	7741-53-9/BI
4	7741-54-0/BI
3537	79-19-6/BI
620	82799-44-8/BI
3	82799-45-9/BI
258	829-20-9/BI
1112	83-38-5/BI
6	86358-85-2/BI
19	89570-85-4/BI

```
             3 90212-73-0/BI
          2647 91-56-5/BI
             8 91912-53-7/BI
           406 93-17-4/BI
          4059 93-55-0/BI
             5 94835-69-5/BI
            20 96799-03-0/BI
             6 96799-04-1/BI
          7795 98-59-9/BI
         15966 98-88-4/BI
         20313 98-95-3/BI
         34885 108-31-6/BI
         17010 108-38-3/BI
           365 119-80-2/BI
           596 1226-42-2/BI
         15362 127464-60-2/BI
             3 306764-68-1/BI
             3 312501-62-5/BI
             3 331945-22-3/BI
             3 353771-45-6/BI
             9 40622-01-3/BI
           258 4506-71-2/BI
             8 5242-26-2/BI
             3 569656-05-9/BI
             3 569656-06-0/BI
             3 569656-29-7/BI
         59933 60-92-4/BI
           453 619-05-6/BI
           104 64900-65-8/BI
          2259 66085-59-4/BI
        375926 7440-70-2/BI
            73 76293-13-5/BI
             4 7741-54-0/BI
           620 82799-44-8/BI
          2647 91-56-5/BI
L34      610421 (108-31-6/BI OR 108-38-3/BI OR 119-80-2/BI OR 1226-42-2/BI OR
                127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-
               3/BI OR 353771-45-6/BI OR 40622-01-3/BI OR 4506-71-2/BI OR 5242-2
               6-2/BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-29-7/BI OR
               60-92-4/BI OR 619-05-6/BI OR 64900-65-8/BI OR 66085-59-4/BI OR
               7440-70-2/BI OR 76293-13-5/BI OR 7741-54-0/BI OR 82799-44-8/BI
               OR 91-56-5/BI OR 108-31-6/BI OR 108-38-3/BI OR 119-80-2/BI OR
               1226-42-2/BI OR 127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/B
               I OR 331945-22-3/BI OR 353771-45-6/BI OR 40622-01-3/BI OR 4506-71
               -2/BI OR 5242-26-2/BI OR 569656-05-9/BI OR 569656-06-0/BI OR
               569656-29-7/BI OR 60-92-4/BI OR 619-05-6/BI OR 64900-65-8/BI OR
               66085-59-4/BI OR 7440-70-2/BI OR 76293-13-5/BI OR 7741-54-0/BI
               OR 82799-44-8/BI OR 91-56-5/BI OR 100-65-2/BI OR 107235-67-6/BI
               OR 108-31-6/BI OR 108-38-3/BI OR 112612-58-5/BI OR 113054-02-7/BI
                OR 120-72-9/BI OR 1226-42-2/BI OR 123-11-5/BI OR 127464-60-2/BI
               OR 13100-05-5/BI OR 13380-67-1/BI

=> s l34 and (cancer or tumor or cancer? or tumour or neoplastic or neoplasm? )
        289571 CANCER
         42241 CANCERS
        300561 CANCER
                 (CANCER OR CANCERS)
        381334 TUMOR
        149800 TUMORS
        428933 TUMOR
                 (TUMOR OR TUMORS)
        304222 CANCER?
          2925 TUMOUR
```

```
          1107 TUMOURS
          3972 TUMOUR
                 (TUMOUR OR TUMOURS)
         55897 NEOPLASTIC
            14 NEOPLASTICS
         55907 NEOPLASTIC
                 (NEOPLASTIC OR NEOPLASTICS)
        433581 NEOPLASM?
L35      24165 L34 AND (CANCER OR TUMOR OR CANCER? OR TUMOUR OR NEOPLASTIC OR
               NEOPLASM? )

=> s l35 and edg
           901 EDG
            25 EDGS
           916 EDG
                 (EDG OR EDGS)
L36        107 L35 AND EDG

=> focus
PROCESSING COMPLETED FOR L36
L37         107 FOCUS L36 1-

=> s e5-e9, e13-e15, e18-e22, e29-e33, e37-e39, e42-e43, e45-e47, e45-e47, e50,
e53-54, e58-e60, e68-e72, e84-e112, e117-e131
         15362 127464-60-2/BI
             3 306764-68-1/BI
             3 312501-62-5/BI
             3 331945-22-3/BI
             3 353771-45-6/BI
             3 569656-05-9/BI
             3 569656-06-0/BI
             3 569656-29-7/BI
           104 64900-65-8/BI
          2259 66085-59-4/BI
        375926 7440-70-2/BI
            73 76293-13-5/BI
             4 7741-54-0/BI
         15362 127464-60-2/BI
             3 306764-68-1/BI
             3 312501-62-5/BI
             3 331945-22-3/BI
             3 353771-45-6/BI
             3 569656-05-9/BI
             3 569656-06-0/BI
             3 569656-29-7/BI
           104 64900-65-8/BI
          2259 66085-59-4/BI
            73 76293-13-5/BI
             4 7741-54-0/BI
           620 82799-44-8/BI
            73 76293-13-5/BI
             4 7741-54-0/BI
           620 82799-44-8/BI
             3 107235-67-6/BI
             3 112612-58-5/BI
             4 113054-02-7/BI
         15362 127464-60-2/BI
            25 13100-05-5/BI
           148 13380-67-1/BI
             4 171286-07-0/BI
             4 173275-26-8/BI
             5 177360-28-0/BI
             6 182762-25-0/BI
```

```
             49 19541-95-8/BI
              2 304650-31-5/BI
              3 306764-68-1/BI
              4 309282-30-2/BI
              2 311773-65-6/BI
              2 311799-07-2/BI
              3 312501-62-5/BI
              2 312519-16-7/BI
              2 312594-43-7/BI
              1 321679-76-9/BI
              3 322662-05-5/BI
              1 327167-87-3/BI
              3 329069-72-9/BI
              2 329350-38-1/BI
              3 330630-42-7/BI
              1 331274-84-1/BI
              3 331945-22-3/BI
              2 332161-39-4/BI
              2 334498-72-5/BI
              2 337349-59-4/BI
              2 337469-26-8/BI
              2 337498-14-3/BI
              1 342384-25-2/BI
              2 346699-98-7/BI
              3 353253-35-7/BI
              3 353273-74-2/BI
              2 353463-50-0/BI
              3 353771-45-6/BI
              3 353793-15-4/BI
              2 355000-90-7/BI
              3 383164-60-1/BI
              5 384729-36-6/BI
             18 385223-15-4/BI
              2 389079-78-1/BI
              5 390105-18-7/BI
              4 390174-36-4/BI
              5 390523-03-2/BI
            132 39151-19-4/BI
              4 392101-34-7/BI
              2 400064-03-1/BI
             28 406-00-8/BI
              9 40622-01-3/BI
             32 43071-45-0/BI
             60 434-75-3/BI
            258 4506-71-2/BI
L38      394370 (127464-60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22
                -3/BI OR 353771-45-6/BI OR  569656-05-9/BI OR 569656-06-0/BI OR
               569656-29-7/BI OR  64900-65-8/BI OR 66085-59-4/BI OR 7440-70-2/BI
                OR 76293-13-5/BI OR 7741-54-0/BI OR  127464-60-2/BI OR 306764-68
               -1/BI OR 312501-62-5/BI OR 331945-22-3/BI OR 353771-45-6/BI OR
               569656-05-9/BI OR 569656-06-0/BI OR 569656-29-7/BI OR  64900-65-8
               /BI OR 66085-59-4/BI OR  76293-13-5/BI OR 7741-54-0/BI OR 82799-4
               4-8/BI OR  76293-13-5/BI OR 7741-54-0/BI OR 82799-44-8/BI OR
               107235-67-6/BI OR  112612-58-5/BI OR 113054-02-7/BI OR  127464-60
               -2/BI OR 13100-05-5/BI OR 13380-67-1/BI OR  171286-07-0/BI OR
               173275-26-8/BI OR 177360-28-0/BI OR 182762-25-0/BI OR 19541-95-8/
               BI OR  304650-31-5/BI OR 306764-68-1/BI OR 309282-30-2/BI OR
               311773-65-6/BI OR 311799-07-2/BI OR 312501-62-5/BI OR 312519-16-7
               /BI OR 312594-43-7/BI OR 321679-76-9/BI OR 322662-05-5/BI OR
               327167-87-3/BI OR 329069-72-9/BI OR 329350-38-1/BI OR 330630-42-7
               /BI OR 331274-84-1/BI OR 331945

=> s e143-e178, e197-e199, e204-206, e214-218, e227-229
```

```
             2 569655-94-3/BI
             2 569655-95-4/BI
             2 569655-96-5/BI
             1 569655-97-6/BI
             2 569655-98-7/BI
             3 569655-99-8/BI
             3 569656-00-4/BI
             2 569656-01-5/BI
             2 569656-02-6/BI
             2 569656-03-7/BI
             1 569656-04-8/BI
             3 569656-05-9/BI
             3 569656-06-0/BI
             1 569656-07-1/BI
             2 569656-08-2/BI
             1 569656-09-3/BI
             2 569656-10-6/BI
             2 569656-11-7/BI
             2 569656-12-8/BI
             2 569656-13-9/BI
             2 569656-14-0/BI
             2 569656-15-1/BI
             1 569656-16-2/BI
             2 569656-17-3/BI
             2 569656-18-4/BI
             2 569656-19-5/BI
             2 569656-20-8/BI
             2 569656-21-9/BI
             1 569656-22-0/BI
             3 569656-23-1/BI
             3 569656-24-2/BI
             2 569656-25-3/BI
             3 569656-26-4/BI
             3 569656-27-5/BI
             2 569656-28-6/BI
             3 569656-29-7/BI
             6 86358-85-2/BI
            19 89570-85-4/BI
             3 90212-73-0/BI
             5 94835-69-5/BI
            20 96799-03-0/BI
             6 96799-04-1/BI
         15362 127464-60-2/BI
             3 306764-68-1/BI
             3 312501-62-5/BI
             3 331945-22-3/BI
             3 353771-45-6/BI
           104 64900-65-8/BI
          2259 66085-59-4/BI
        375926 7440-70-2/BI
L39     392992 (569655-94-3/BI OR 569655-95-4/BI OR 569655-96-5/BI OR 569655-97
               -6/BI OR 569655-98-7/BI OR 569655-99-8/BI OR 569656-00-4/BI OR
               569656-01-5/BI OR 569656-02-6/BI OR 569656-03-7/BI OR 569656-04-8
               /BI OR 569656-05-9/BI OR 569656-06-0/BI OR 569656-07-1/BI OR
               569656-08-2/BI OR 569656-09-3/BI OR 569656-10-6/BI OR 569656-11-7
               /BI OR 569656-12-8/BI OR 569656-13-9/BI OR 569656-14-0/BI OR
               569656-15-1/BI OR 569656-16-2/BI OR 569656-17-3/BI OR 569656-18-4
               /BI OR 569656-19-5/BI OR 569656-20-8/BI OR 569656-21-9/BI OR
               569656-22-0/BI OR 569656-23-1/BI OR 569656-24-2/BI OR 569656-25-3
               /BI OR 569656-26-4/BI OR 569656-27-5/BI OR 569656-28-6/BI OR
               569656-29-7/BI OR  86358-85-2/BI OR 89570-85-4/BI OR 90212-73-0/B
               I OR  94835-69-5/BI OR 96799-03-0/BI OR 96799-04-1/BI OR  127464-
               60-2/BI OR 306764-68-1/BI OR 312501-62-5/BI OR 331945-22-3/BI OR
```

353771-45-6/BI OR 64900-65-8/BI OR 66085-59-4/BI OR 7440-70-2/BI

```
=> s l39 or l38
L40     394405 L39 OR L38

=> s l40 and (cancer or tumor or cancer? or tumour or neoplastic or neoplasm? )
        289571 CANCER
         42241 CANCERS
        300561 CANCER
                 (CANCER OR CANCERS)
        381334 TUMOR
        149800 TUMORS
        428933 TUMOR
                 (TUMOR OR TUMORS)
        304222 CANCER?
          2925 TUMOUR
          1107 TUMOURS
          3972 TUMOUR
                 (TUMOUR OR TUMOURS)
         55897 NEOPLASTIC
            14 NEOPLASTICS
         55907 NEOPLASTIC
                 (NEOPLASTIC OR NEOPLASTICS)
        433581 NEOPLASM?
L41      16562 L40 AND (CANCER OR TUMOR OR CANCER? OR TUMOUR OR NEOPLASTIC OR
               NEOPLASM? )

=> e edg and l41
E1            2     EDFV/BI
E2          901     EDG/BI
E3            0 --> EDG AND L41/BI
E4          146     EDG1/BI
E5            1     EDG1C/BI
E6          113     EDG2/BI
E7           71     EDG3/BI
E8            1     EDG34/BI
E9            1     EDG3SB/BI
E10          61     EDG4/BI
E11           1     EDG4NON/BI
E12          56     EDG5/BI

=> s edg and l41
            901 EDG
             25 EDGS
            916 EDG
                  (EDG OR EDGS)
L42          54 EDG AND L41

=> focus
PROCESSING COMPLETED FOR L42
L43          54 FOCUS L42 1-

=> d ibib abs hitstr 1-54

L43  ANSWER 1 OF 54  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:591307  CAPLUS
DOCUMENT NUMBER:          139:143997
TITLE:                    Methods using Edg receptor modulators for
                          the treatment of Edg receptor-associated
                          conditions
INVENTOR(S):              Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
                          V.; Gluchowski, Charles
PATENT ASSIGNEE(S):       Ceretek LLC, USA
```

SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	AA	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T2	20050707	JP 2003-562260	20030121
US 2005261298	A1	20051124	US 2003-390428	20030314
PRIORITY APPLN. INFO.:			US 2002-350445P	P 20020118
			US 2002-350446P	P 20020118
			US 2002-350447P	P 20020118
			US 2002-350448P	P 20020118
			WO 2003-US1881	W 20030121
			US 2003-352579	B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an **Edg**-2, **Edg**-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the **Edg**-2, **Edg**-3, **Edg**-4 or **Edg** 7 receptor is contacted with a modulator of the **Edg** -2, **Edg**-3, Ed-4 or **Edg** 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg**-2, **Edg** -3, Ed-4 or **Edg**-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the **Edg**-2, **Edg**-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT **182762-25-0**, GenBank X83864 **384729-36-6**, GenBank U78192 **385223-15-4**, GenBank AF011466 **390105-18-7**, GenBank AF034780 **390174-36-4**, GenBank AF233365 **390523-03-2**, GenBank AF317676 **392101-34-7**, GenBank AF127138
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)

RN 182762-25-0 CAPLUS
CN DNA (human gene EDG-3 plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 384729-36-6 CAPLUS
CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 385223-15-4 CAPLUS
CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390105-18-7 CAPLUS
CN GenBank AF034780 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390174-36-4 CAPLUS
CN DNA (human gene CHEDG1 cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390523-03-2 CAPLUS
CN GenBank AF317676 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 392101-34-7 CAPLUS
CN GenBank AF127138 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **353273-74-2P 569655-94-3P 569655-95-4P**
569655-96-5P 569656-23-1P 569656-24-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)
RN 353273-74-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI) (CA INDEX NAME)



RN 569655-94-3 CAPLUS
CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 569655-95-4 CAPLUS
CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 569655-96-5 CAPLUS
CN 1,2,4-Triazin-3(2H)-one, 4,5-dihydro-5-(1H-indol-3-yl)-6-phenyl-, (+)-
(9CI) (CA INDEX NAME)

Rotation (+).



RN 569656-23-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-24-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **94835-69-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)
RN 94835-69-5 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT **40622-01-3P 173275-26-8P 304650-31-5P**
311799-07-2P 312501-62-5P 312519-16-7P
331945-22-3P 334498-72-5P 342384-25-2P
353253-35-7P 353771-45-6P 355000-90-7P
569656-08-2P 569656-09-3P 569656-10-6P
569656-11-7P 569656-12-8P 569656-13-9P
569656-14-0P 569656-15-1P 569656-16-2P
569656-17-3P 569656-18-4P 569656-19-5P
569656-20-8P 569656-21-9P 569656-25-3P
569656-26-4P 569656-27-5P 569656-29-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)
RN 40622-01-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 173275-26-8 CAPLUS
CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 304650-31-5 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2,6-dichlorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 311799-07-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chloro-6-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 312501-62-5 CAPLUS
CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)



RN 312519-16-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2,3-dichlorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 331945-22-3 CAPLUS
CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 334498-72-5 CAPLUS
CN 3(2H)-Isoquinolinone, 1-(2,6-dichlorophenyl)-1,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 342384-25-2 CAPLUS
CN 2H-Indol-2-one, 3-(2-amino-4-oxo-5(4H)-thiazolylidene)-1,3-dihydro-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 353253-35-7 CAPLUS
CN Acetic acid, [[2-[(4,5-diphenyl-2-thiazolyl)amino]-2-oxoethyl]thio]- (9CI) (CA INDEX NAME)



RN 353771-45-6 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 355000-90-7 CAPLUS
CN 4-Quinolinecarboxamide, N-[(4-fluorophenyl)methyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 569656-08-2 CAPLUS
CN Butanamide, N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-09-3 CAPLUS
CN Butanamide, N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-10-6 CAPLUS
CN Butanamide, 4,4,4-trifluoro-N-[5-(4-fluorophenyl)-1H-pyrazol-3-yl]-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-11-7 CAPLUS
CN Butanamide, 2-chloro-4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



RN 569656-12-8 CAPLUS
CN Butanamide, N-[5-(3,5-dimethoxyphenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-13-9 CAPLUS
CN Butanamide, 4,4,4-trifluoro-N-[5-(3-methoxyphenyl)-1H-pyrazol-3-yl]-3-oxo-(9CI) (CA INDEX NAME)



RN 569656-14-0 CAPLUS
CN Butanamide, N-[5-(1,3-benzodioxol-5-yl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-15-1 CAPLUS
CN Butanamide, 4,4,4-trifluoro-2-methyl-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



RN 569656-16-2 CAPLUS
CN 1H-Pyrazole-1-carboxamide, 3-phenyl-N-2-propenyl-5-[(4,4,4-trifluoro-2-methyl-1,3-dioxobutyl)amino]- (9CI) (CA INDEX NAME)



RN 569656-17-3 CAPLUS
CN Butanamide, N-[5-(2-bromophenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-18-4 CAPLUS
CN Butanamide, N-[5-(2,4-dimethoxyphenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxo- (9CI) (CA INDEX NAME)



RN 569656-19-5 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(2-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 569656-20-8 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(3-thienyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 569656-21-9 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-oxo-N-[5-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 569656-25-3 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-[(4-fluorophenyl)hydroxyamino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-26-4 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-27-5 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-29-7 CAPLUS
CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



IT **90212-73-0 107235-67-6 171286-07-0**
177360-28-0 306764-68-1 309282-30-2
311773-65-6 312594-43-7 321679-76-9
322662-05-5 327167-87-3 329350-38-1
330630-42-7 331274-84-1 332161-39-4
337349-59-4 337469-26-8 337498-14-3
346699-98-7 353463-50-0 353793-15-4
383164-60-1 389079-78-1 400064-03-1
569655-97-6 569655-98-7 569656-22-0
569656-28-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)

RN 90212-73-0 CAPLUS
CN s-Indacene-4-methanol, α-[(diethylamino)methyl]-1,2,3,5,6,7-hexahydro- (9CI) (CA INDEX NAME)



RN 107235-67-6 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)



RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 177360-28-0 CAPLUS
CN 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 306764-68-1 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 309282-30-2 CAPLUS
CN Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 311773-65-6 CAPLUS
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 312594-43-7 CAPLUS
CN Benzoic acid, 2-[[(6-ethoxy-2-benzothiazolyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 321679-76-9 CAPLUS
CN Carbamic acid, [2-[(2,4,6-trimethylphenyl)amino]-1,3-benzodioxol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 322662-05-5 CAPLUS
CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 327167-87-3 CAPLUS
CN 3-Thiophenecarbonitrile, 4-amino-2-(ethylamino)-5-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 329350-38-1 CAPLUS
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



RN 330630-42-7 CAPLUS
CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 331274-84-1 CAPLUS
CN Cyclopropanecarboxamide, N-(3-chloro-2-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 332161-39-4 CAPLUS
CN Acetamide, 2-[[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 337349-59-4 CAPLUS
CN Urea, N-[3-[[(cyclohexylamino)carbonyl]amino]propyl]-N'-(2-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 337469-26-8 CAPLUS
CN Ethanol, 2-[[(7-chlorobenzo[b]thien-3-yl)methyl]ethylamino]- (9CI) (CA INDEX NAME)



RN 337498-14-3 CAPLUS
CN Acetamide, N-(2-ethylphenyl)-2-[[4-(4-methylphenyl)-1H-imidazol-2-yl]thio]-

(9CI) (CA INDEX NAME)



RN 346699-98-7 CAPLUS
CN Benzamide, 2,5-dichloro-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 353463-50-0 CAPLUS
CN Glycine, N-[[[3-cyano-4-(4-fluorophenyl)-6-phenyl-2-pyridinyl]thio]acetyl]- (9CI) (CA INDEX NAME)



RN 353793-15-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI) (CA INDEX NAME)



RN 383164-60-1 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 389079-78-1 CAPLUS
CN 4-Quinolinecarboxamide, N-[(4-chlorophenyl)methyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 400064-03-1 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[2-(diethylamino)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 569655-97-6 CAPLUS
CN Carbamic acid, (1H-benzimidazol-2-ylmethyl)-, (4-chloro-3-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 569655-98-7 CAPLUS
CN Piperazine, 1-(2,3-dichloro-6-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 569656-22-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethylphenyl)imino]-1,3-dihydro-1-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 569656-28-6 CAPLUS
CN Thiourea, N-1,3-benzodioxol-5-yl-N'-(3,5-dichlorophenyl)-N-ethyl- (9CI) (CA INDEX NAME)



IT **406-00-8**, 4-Fluorophenylhydroxylamine **434-75-3**, 2-Chloro-6-fluorobenzoic acid **4506-71-2 13100-05-5 13380-67-1 19541-95-8 39151-19-4 64900-65-8**, 2-Chlorobenzenesulfonyl isocyanate **82799-44-8 89570-85-4 96799-03-0 96799-04-1 569656-04-8 569656-05-9 569656-06-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)

RN 406-00-8 CAPLUS
CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 434-75-3 CAPLUS
CN Benzoic acid, 2-chloro-6-fluoro- (8CI, 9CI) (CA INDEX NAME)



RN 4506-71-2 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 13100-05-5 CAPLUS
CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 13380-67-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1-(4-bromophenyl)- (9CI) (CA INDEX NAME)



RN 19541-95-8 CAPLUS
CN 1H-Pyrazol-3-amine, 5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 39151-19-4 CAPLUS
CN Ethanone, 1-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 64900-65-8 CAPLUS
CN Benzenesulfonyl isocyanate, 2-chloro- (9CI) (CA INDEX NAME)



RN 82799-44-8 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-diethyl- (9CI) (CA INDEX NAME)



RN 89570-85-4 CAPLUS
CN 2(1H)-Pyridinone, 5-(trifluoromethyl)-, hydrazone (9CI) (CA INDEX NAME)



RN 96799-03-0 CAPLUS
CN 1H-Pyrazol-3-amine, 5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 96799-04-1 CAPLUS
CN 1H-Pyrazol-3-amine, 5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 569656-04-8 CAPLUS
CN Benzoic acid, 2-[(2-formylphenyl)dithio]- (9CI) (CA INDEX NAME)



RN 569656-05-9 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-06-0 CAPLUS
CN Hydrazinecarbothioamide, 2-(1-pentylhexylidene)- (9CI) (CA INDEX NAME)



IT **7741-54-0P 43071-45-0P 76293-13-5P**
86358-85-2P 112612-58-5P 113054-02-7P

329069-72-9P 569655-99-8P 569656-00-4P
569656-01-5P 569656-02-6P 569656-03-7P
569656-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)

RN 7741-54-0 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-dimethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



RN 43071-45-0 CAPLUS
CN 4-Quinolinecarboxylic acid, 3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 76293-13-5 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 86358-85-2 CAPLUS
CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 112612-58-5 CAPLUS
CN Hydrazinecarbothioamide, 2-[(2,4-dimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 113054-02-7 CAPLUS
CN 2H-Indol-2-one, 3-(2-amino-4-oxo-5(4H)-thiazolylidene)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 329069-72-9 CAPLUS
CN Hydrazinecarbothioamide, 2-[(3,5-dimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 569655-99-8 CAPLUS
CN 1H-Pyrazol-3-amine, 5-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 569656-00-4 CAPLUS
CN Acetamide, N-[5-(4-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 569656-01-5 CAPLUS
CN Benzoic acid, 2-chloro-6-fluoro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)



RN 569656-02-6 CAPLUS
CN Benzoic acid, 2,3-dichloro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)



RN 569656-03-7 CAPLUS
CN Benzoic acid, 2,6-dichloro-, 2-[5-(trifluoromethyl)-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)



RN 569656-07-1 CAPLUS
CN Benzenamine, N-[2-(4-methoxyphenyl)ethylidene]-, N-oxide (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; **Edg** receptor modulators for treatment of

Edg receptor-associated conditions)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; **Edg** receptor modulators for treatment of **Edg** receptor-associated conditions)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 2 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:259685 CAPLUS
DOCUMENT NUMBER: 142:309943
TITLE: Methods using **Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005065194	A1	20050324	US 2004-760061		20040116
PRIORITY APPLN. INFO.:			US 2003-440341P	P	20030116

OTHER SOURCE(S): MARPAT 142:309943
AB In one aspect, the invention provides a method for modulating an **Edg**-2 receptor-mediated biol. activity in a cell. A cell expressing the **Edg**-2 receptor is contacted with an modulator of the **Edg**-2 receptor, which modulates the **Edg**-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating **Edg**-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg**-2 receptor is administered to the subject. Compds. of the invention include pyrrolidine-2,5-dione derivs. (preparation included).
IT **127464-60-2**, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **94835-69-5**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)
RN 94835-69-5 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT **353273-74-2P 569656-23-1P 569656-24-2P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)

RN 353273-74-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI) (CA INDEX NAME)



RN 569656-23-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-24-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **173275-26-8P 569656-25-3P 569656-26-4P 569656-27-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)

RN 173275-26-8 CAPLUS
CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 569656-25-3 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-[(4-fluorophenyl)hydroxyamino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-26-4 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-27-5 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **353793-15-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)
RN 353793-15-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI) (CA INDEX NAME)



IT **406-00-8**, 4-Fluorophenylhydroxylamine **13380-67-1**, N-(4-Bromophenyl)maleimide
RL: RCT (Reactant); RACT (Reactant or reagent)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)

RN 406-00-8 CAPLUS
CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 13380-67-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 1-(4-bromophenyl)- (9CI) (CA INDEX NAME)



IT **13100-05-5P 86358-85-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)
RN 13100-05-5 CAPLUS
CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 86358-85-2 CAPLUS
CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; **Edg**-2 receptor modulators for treatment of **edg**-2 receptor-associated conditions)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 3 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1242755 CAPLUS
DOCUMENT NUMBER: 143:472565
TITLE: Methods of treating conditions associated with an **Edg**-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 352,579.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261298	A1	20051124	US 2003-390428	20030314
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2002-350446P	P	20020118
WO 2003-US1881	A1	20030121
US 2003-352579	B2	20030127
US 2002-350445P	P	20020118
US 2002-350447P	P	20020118
US 2002-350448P	P	20020118

OTHER SOURCE(S): MARPAT 143:472565

AB In one aspect, the present invention provides a method for modulating an **Edg**-7 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-7 receptor is contacted with a modulator of the **Edg**-7 receptor which is capable of modulating an **Edg**-7 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg**-7 receptor mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the **Edg**-7 receptor is administered to the subject.

IT **127464-60-2**, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**Edg**-7 modulators for treating conditions associated with **Edg**-7 receptor)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **40622-01-3P**, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid **66085-59-4P 306764-68-1P 312501-62-5P 331945-22-3P 353771-45-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg**-7 modulators for treating conditions associated with **Edg**-7 receptor)

RN 40622-01-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 66085-59-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 306764-68-1 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 312501-62-5 CAPLUS
CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)



RN 331945-22-3 CAPLUS
CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 353771-45-6 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **4506-71-2**, Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate **64900-65-8**, 2-Chlorobenzenesulfonyl isocyanate **82799-44-8 569656-05-9 569656-06-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(**Edg**-7 modulators for treating conditions associated with **Edg**-7 receptor)

RN 4506-71-2 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 64900-65-8 CAPLUS
CN Benzenesulfonyl isocyanate, 2-chloro- (9CI) (CA INDEX NAME)



RN 82799-44-8 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-diethyl- (9CI) (CA INDEX NAME)



RN 569656-05-9 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-06-0 CAPLUS
CN Hydrazinecarbothioamide, 2-(1-pentylhexylidene)- (9CI) (CA INDEX NAME)



IT **7741-54-0P 76293-13-5P**, 2,4-Dimethylthioxanthen-9-one
569656-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**Edg**-7 modulators for treating conditions associated with **Edg**-7 receptor)
RN 7741-54-0 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-dimethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



RN 76293-13-5 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 569656-29-7 CAPLUS
CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transport; **Edg**-7 modulators for treating conditions associated with **Edg**-7 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 4 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:171122 CAPLUS
DOCUMENT NUMBER: 138:335399
TITLE: Biochemical regulation of breast **cancer** cell expression of S1P2 (**Edg**-5) and S1P3 (**Edg**-3) G protein-coupled receptors for sphingosine 1-phosphate
AUTHOR(S): Dolezalova, Hana; Shankar, Geetha; Huang, Mei-Chuan; Bikle, Daniel D.; Goetzl, Edward J.
CORPORATE SOURCE: Departments of Medicine and Microbiology-Immunology, University of California, San Francisco, CA, 94143-0711, USA

SOURCE: Journal of Cellular Biochemistry (2003), 88(4), 732-743
CODEN: JCEBD5; ISSN: 0730-2312
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB G protein-coupled receptors (GPCRs) for lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) transduce signals to many functions of normal cells. Most human **cancer** cells upregulates S1P and LPA GPCRs, in patterns distinctive for each type of **tumor**. The findings that 1-alpha, 25-dihydroxy-vitamin D3 (VD3) and all-trans retinoic acid (RA) differentially alter expression of the predominant S1P3 (**Edg**-3) R and S1P2 (**Edg**-5) R in human breast **cancer** cells (BCCs) permitted analyses of their individual activities, despite a lack of selective pharmacol. probes. S1P-evoked increases in [Ca2+]i in S1P3 R-predominant BCCs were suppressed by concns. of VD3 and RA which decreased expression of S1P3 Rs, despite RA-induced increases in S1P2 Rs. S1P-elicited chemokinetic migration of S1P3 R-predominant BCCs across a type IV collagen-coated micropore filter also was inhibited by concns. of VD3 and RA which decreased expression of S1P3 Rs. The RA-induced increase in expression of S1P2 Rs did not prevent suppression by RA of S1P-elicited chemokinesis, which appears to be mediated by S1P3 Rs, but instead exposed S1P2 R-mediated inhibition of epidermal growth factor-stimulated chemotaxis of BCCs. In contrast, expression of the predominant LPA2 Rs, LPA-evoked increase in [Ca2+]i and LPA-stimulated chemokinetic migration were suppressed concomitantly by RA but not VD3. Thus two structurally-homologous S1P Rs of BCCs differ in coupling to [Ca2+]i signaling and have opposite effects on protein growth factor-stimulated chemotaxis.

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(two structurally-homologous S1P Rs of BCCs differ in coupling to [Ca2+]i signaling and have opposite effects on protein growth factor-stimulated chemotaxis)

RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 5 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409218 CAPLUS
DOCUMENT NUMBER: 142:441857
TITLE: Methods of treating conditions associated with an **edg**-2 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 347,420, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101518	A1	20050512	US 2003-390427	20030314

PRIORITY APPLN. INFO.: US 2002-350448P P 20020118
US 2003-347420 B2 20030117

OTHER SOURCE(S): MARPAT 142:441857

GI



I

AB In one aspect, the present invention provides a method for modulating an **Edg**-2 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-2 receptor is contacted with an modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the **Edg**-2 receptor, which modulates the **Edg**-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating **Edg**-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg**-2 receptor is administered to the subject.

IT **7440-70-2**, Calcium, biological studies **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treating conditions associated with an **edg**-2 receptor)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **94835-69-5**
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods of treating conditions associated with an **edg**-2 receptor)

RN 94835-69-5 CAPLUS

CN Butanamide, 4,4,4-trifluoro-3-oxo-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



IT **173275-26-8P 353273-74-2P 569656-26-4P 569656-27-5P**

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating conditions associated with an **edg**-2 receptor)

RN 173275-26-8 CAPLUS
CN Phenol, 2-(1-ethyl-3-methyl-5-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 353273-74-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)- (9CI) (CA INDEX NAME)



RN 569656-26-4 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3R,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-27-5 CAPLUS
CN 2H-Pyrrolo[3,4-d]isoxazole-4,6(3H,5H)-dione, 5-(4-bromophenyl)dihydro-3-(4-methoxyphenyl)-2-phenyl-, (3S,3aS,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **309282-30-2P 322662-05-5P 330630-42-7P 353793-15-4P 383164-60-1P 569656-23-1P 569656-24-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating conditions associated with an **edg**-2 receptor)

RN 309282-30-2 CAPLUS
CN Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 322662-05-5 CAPLUS
CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 330630-42-7 CAPLUS
CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 353793-15-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(hydroxyphenylamino)-1-(2-propoxyphenyl)- (9CI) (CA INDEX NAME)



RN 383164-60-1 CAPLUS
CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-23-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 569656-24-2 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(2-ethoxyphenyl)-3-(hydroxyphenylamino)-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **406-00-8**, 4-Fluorophenylhydroxylamine **86358-85-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods of treating conditions associated with an **edg**-2 receptor)
RN 406-00-8 CAPLUS
CN Benzenamine, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 86358-85-2 CAPLUS
CN 2-Propanone, 1-[2-(benzoyloxy)phenyl]- (9CI) (CA INDEX NAME)



IT **13100-05-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treating conditions associated with an **edg**-2 receptor)

RN 13100-05-5 CAPLUS
CN 2-Propanone, 1-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L43 ANSWER 6 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703129 CAPLUS
DOCUMENT NUMBER: 141:218996
TITLE: Methods using **Edg**-7 modulators for treating conditions associated with an **Edg**-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167192	A1	20040826	US 2004-760002		20040116
PRIORITY APPLN. INFO.:			US 2003-440321P	P	20030116
			US 2003-454881P	P	20030313

OTHER SOURCE(S): MARPAT 141:218996

AB The invention provides a method for modulating an **Edg**-7 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-7 receptor is contacted with a modulator of the **Edg**-7 receptor which is capable of modulating an **Edg**-7 receptor-mediated biol. activity. The invention also provides a method for modulating an **Edg**-7 receptor-mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the **Edg**-7 receptor is administered to the subject. Preparation of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.

IT **312501-62-5P 331945-22-3P 353771-45-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**Edg**-7 modulators for treating conditions associated with an **Edg**-7 receptor)

RN 312501-62-5 CAPLUS
CN 5-Thiazoleacetic acid, 4,5-dihydro-4-oxo-2-[(1-pentylhexylidene)hydrazino]- (9CI) (CA INDEX NAME)



RN 331945-22-3 CAPLUS
CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 353771-45-6 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **569656-05-9 569656-06-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(**Edg**-7 modulators for treating conditions associated with an **Edg**-7 receptor)
RN 569656-05-9 CAPLUS
CN Acetic acid, [4-bromo-2-[[2-[(4-chlorophenyl)amino]-4-oxo-5(4H)-thiazolylidene]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 569656-06-0 CAPLUS
CN Hydrazinecarbothioamide, 2-(1-pentylhexylidene)- (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; **Edg**-7 modulators for treating conditions associated with an **Edg**-7 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; **Edg**-7 modulators for treating conditions associated with an **Edg**-7 receptor)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 7 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703126 CAPLUS
DOCUMENT NUMBER: 141:200234
TITLE: Methods of treating conditions associated with the **Edg**-3 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167181	A1	20040826	US 2004-760003		20040116
PRIORITY APPLN. INFO.:			US 2003-440322P	P	20030116
			US 2003-454880P	P	20030313

OTHER SOURCE(S): MARPAT 141:200234
AB The invention provides a method of inhibiting the **Edg**-3 receptor-mediated biol. activity in a cell. A cell expressing the **Edg**-3 receptor is contacted with an amount of an **Edg**-3 receptor inhibitor sufficient to inhibit the **Edg**-3 receptor-mediated biol. activity. Preferably, the inhibitor is not a phospholipid. Also the invention provides a method where an **Edg** -3 receptor-mediated biol. activity is inhibited in a subject. A therapeutically effective amount of an inhibitor of the **Edg**-3 receptor is administered to the subject. Preferably, the inhibitor is not a phospholipid.
IT **7440-70-2**, Calcium, biological studies **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(methods of treating conditions associated with **Edg**-3 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **177360-28-0 332161-39-4 346699-98-7**
355000-90-7 389079-78-1 569656-28-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating conditions associated with **Edg**-3 receptor)
RN 177360-28-0 CAPLUS
CN 4-Quinolinecarboxamide, 3-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 332161-39-4 CAPLUS
CN Acetamide, 2-[[5-(2-hydroxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 346699-98-7 CAPLUS
CN Benzamide, 2,5-dichloro-N-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 355000-90-7 CAPLUS
CN 4-Quinolinecarboxamide, N-[(4-fluorophenyl)methyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 389079-78-1 CAPLUS
CN 4-Quinolinecarboxamide, N-[(4-chlorophenyl)methyl]-3-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 569656-28-6 CAPLUS
CN Thiourea, N-1,3-benzodioxol-5-yl-N'-(3,5-dichlorophenyl)-N-ethyl- (9CI) (CA INDEX NAME)



IT **4506-71-2**

RL: RCT (Reactant); RACT (Reactant or reagent)
(methods of treating conditions associated with **Edg**-3 receptor)
RN 4506-71-2 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-amino-4,5,6,7-tetrahydro-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



L43 ANSWER 8 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80878 CAPLUS
DOCUMENT NUMBER: 140:139547
TITLE: Screening for substituted aryl isoxazole effectors of the **Edg**-1 receptor for the treatment of receptor-associated conditions
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Gluchowski, Charles; Spencer, Juliet V.
PATENT ASSIGNEE(S): Ceretek Llc, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004009816	A1	20040129	WO 2003-US22463		20030717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2466288	AA	20040129	CA 2003-2466288		20030717
AU 2003252023	A1	20040209	AU 2003-252023		20030717
US 2004147562	A1	20040729	US 2003-621966		20030717
EP 1523556	A1	20050420	EP 2003-765716		20030717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005533852	T2	20051110	JP 2004-523557		20030717
PRIORITY APPLN. INFO.:			US 2002-397299P	P	20020718
			WO 2003-US22463	W	20030717

OTHER SOURCE(S): MARPAT 140:139547
AB In one aspect, the present invention provides a method of modulating an **Edg**-1 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-1 receptor is contacted with a modulator of the **Edg**-1 receptor sufficient to modulate the **Edg**-1 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an **Edg**-1 receptor mediated biol. activity in a subject. A therapeutically effective amount of

a modulator of the **Edg**-1 receptor is administered to the subject.

IT **182762-25-0**, GenBank X83864 **384729-36-6**, GenBank U78192 **385223-15-4**, GenBank AF011466 **390105-18-7**, GenBank AF034780 **390174-36-4**, GenBank AF233365 **390523-03-2**, GenBank AF317676 **392101-34-7**, GenBank AF127138
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(screening for substituted aryl isoxazole effectors of **Edg**-1 receptor for treatment of receptor-associated conditions)

RN 182762-25-0 CAPLUS
CN DNA (human gene EDG-3 plus flanks) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 384729-36-6 CAPLUS
CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 385223-15-4 CAPLUS
CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390105-18-7 CAPLUS
CN GenBank AF034780 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390174-36-4 CAPLUS
CN DNA (human gene CHEDG1 cDNA) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 390523-03-2 CAPLUS
CN GenBank AF317676 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 392101-34-7 CAPLUS
CN GenBank AF127138 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 9 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:612479 CAPLUS
DOCUMENT NUMBER: 141:138524
TITLE: Gene expression profiles and microarrays for colon **cancer** and their use for **cancer** diagnosis and therapeutics
INVENTOR(S): Eveleigh, Deepa; Bigwood, Douglas; Taylor, Ian
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 23 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004146921	A1	20040729	US 2004-764425	20040123
CA 2514187	AA	20040812	CA 2004-2514187	20040123
WO 2004066941	A2	20040812	WO 2004-US2188	20040123
WO 2004066941	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1603514 A2 20051214 EP 2004-704977 20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2003-442582P P 20030124
WO 2004-US2188 W 20040123

AB The present invention relates to gene expression profiles for colon **cancer**, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using the expression profiles and microarrays. The invention also provides methods and compns. for diagnostic assays for detecting **cancer** and therapeutic methods and compns. for treating **cancer**. The invention also provides methods for designing, identifying, and optimizing therapeutics for **cancer**. [The present invention claims a total of 96 nucleic acid sequences and 95 protein sequences and provides their GenBank or RefSeq accession nos., but the Sequence Listing was not made available on publication of the patent application.].

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene expression profiles and microarrays for colon **cancer** and their use for **cancer** diagnosis and therapeutics)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 10 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703127 CAPLUS
DOCUMENT NUMBER: 141:200235
TITLE: Methods of treating conditions associated with an **Edg**-3 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167185	A1	20040826	US 2004-760064	20040116

PRIORITY APPLN. INFO.: US 2003-440325P P 20030116
OTHER SOURCE(S): MARPAT 141:200235

AB The invention provides a method of inhibiting the **Edg**-3 receptor - mediated biol. activity in a cell. A cell expressing the **Edg** -3 receptor is contacted with an amount of an **Edg**-3 receptor inhibitor sufficient to inhibit the **Edg**-3 receptor - mediated biol. activity. Preferably, the inhibitor is not a phospholipid. Also the invention provides a method where an **Edg**-3 receptor - mediated biol. activity is inhibited in a subject. A therapeutically effective amount of an inhibitor of the **Edg**-3 receptor is

administered to the subject. Preferably, the inhibitor is not a phospholipid.

IT **7440-70-2**, Calcium, biological studies **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treating conditions associated with **Edg**-3 receptor)

RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **107235-67-6 171286-07-0 311773-65-6 329350-38-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating conditions associated with **Edg**-3 receptor)

RN 107235-67-6 CAPLUS
CN 4,6(1H,5H)-Pyrimidinedione, 5-ethyl-2-[(4-methoxyphenyl)amino]-5-(1-methylbutyl)- (9CI) (CA INDEX NAME)



RN 171286-07-0 CAPLUS
CN 4H-Naphtho[1,2-b]pyran-3-carboxylic acid, 2-amino-4-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 311773-65-6 CAPLUS
CN Acetamide, N-(1,7-diphenyl-2,3,6,7-tetrahydro-1H,5H-benzo[ij]quinolizin-9-yl)- (9CI) (CA INDEX NAME)



RN 329350-38-1 CAPLUS
CN 3,5-Piperidinediacetic acid, 4-oxo-2,6-diphenyl-, bis(1-methylethyl) ester (9CI) (CA INDEX NAME)



L43 ANSWER 11 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703122 CAPLUS
DOCUMENT NUMBER: 141:200233
TITLE: Methods of treating conditions associated with an **Edg**-2 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167132	A1	20040826	US 2004-760063		20040116
PRIORITY APPLN. INFO.:			US 2003-440337P	P	20030116

OTHER SOURCE(S): MARPAT 141:200233
AB The invention provides a method for modulating an **Edg**-2 receptor-mediated biol. activity in a cell. A cell expressing the **Edg**-2 receptor is contacted with an modulator of the **Edg** -2 receptor, which modulates the **Edg**-2 receptor mediated biol. activity. In another aspect, the invention provides a method for modulating **Edg**-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg**-2 receptor is administered to the subject.
IT **7440-70-2**, Calcium, biological studies **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treating conditions associated with an **Edg**-2 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **384729-36-6**, GenBank U78192

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(methods of treating conditions associated with an **Edg**-2 receptor)
RN 384729-36-6 CAPLUS
CN GenBank U78192 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **322662-05-5 330630-42-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating conditions associated with an **Edg**-2 receptor)
RN 322662-05-5 CAPLUS
CN Benzaldehyde, 3-bromo-4-hydroxy-5-methoxy-, [4,6-bis(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



RN 330630-42-7 CAPLUS
CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)



L43 ANSWER 12 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:803937 CAPLUS
DOCUMENT NUMBER: 141:307509
TITLE: Methods of treating conditions associated with an **Edg**-2 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004192739	A1	20040930	US 2004-759992		20040116
PRIORITY APPLN. INFO.:			US 2003-440340P	P	20030116
			US 2003-455112P	P	20030313

OTHER SOURCE(S): MARPAT 141:307509

AB In one aspect, the present invention provides a method for modulating an **Edg**-2 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-2 receptor is contacted with an modulator of the **Edg**-2 receptor, which modulates the **Edg**-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating **Edg**-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the **Edg**-2 receptor is administered to the subject.

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transport; treating conditions associated with **Edg**-2 receptor)

RN 7440-70-2 CAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treating conditions associated with **Edg**-2 receptor)

RN 127464-60-2 CAPLUS

CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **309282-30-2 383164-60-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating conditions associated with **Edg**-2 receptor)

RN 309282-30-2 CAPLUS

CN Spiro[3H-indole-3,2'(3'H)-[1,3,4]thiadiazol]-2(1H)-one, 5-methyl-5'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 383164-60-1 CAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 4-[(2-hydroxyphenyl)amino]-6,6-dimethyl-2-oxo-3-(1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)



L43 ANSWER 13 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:703124 CAPLUS
DOCUMENT NUMBER: 141:218944
TITLE: Treating conditions associated with an **Edg**-7 receptor
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167165	A1	20040826	US 2004-760062		20040116
PRIORITY APPLN. INFO.:			US 2003-440336P	P	20030116

OTHER SOURCE(S): MARPAT 141:218944
GI



I



II

AB The invention provides a method for modulating an **Edg**-7 receptor mediated biol. activity in a cell. A cell expressing the **Edg**-7 receptor is contacted with a modulator of the **Edg**-7 receptor which is capable of modulating an **Edg**-7 receptor mediated biol. activity. The invention provides a method for modulating an **Edg** -7 receptor mediated biol. activity in a subject. A therapeutically effective amount of the **Edg**-7 receptor modulator with formula I (where R1,R2 R3 R4 and R7 = -H,-halo,-CN, -NO2 etc. independently) or with formula II (where R1, R2, R3, R4 and R7 = -H,-halo, -NO2 -CN, etc.) or a pharmaceutically available solvate or hydrate therof is administered to the subject.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of treating conditions associated with an **Edg**-7 receptor)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **40622-01-3P 66085-59-4P 306764-68-1P 569656-29-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of treating conditions associated with an **Edg**-7 receptor)

RN 40622-01-3 CAPLUS
CN 6-Quinoxalinecarboxylic acid, 2,3-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 66085-59-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 306764-68-1 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 569656-29-7 CAPLUS
CN 9H-Thioxanthene, 2,4-diethyl-, 10,10-dioxide (9CI) (CA INDEX NAME)



IT **76293-13-5P**, 2,4-Dimethylthioxanthen-9-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of treating conditions associated with an **Edg**-7 receptor)
RN 76293-13-5 CAPLUS
CN 9H-Thioxanthen-9-one, 2,4-dimethyl- (9CI) (CA INDEX NAME)



IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transport; methods of treating conditions associated with an **Edg**-7 receptor)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 14 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:320060 CAPLUS
DOCUMENT NUMBER: 134:339179
TITLE: Nucleic acids and proteins associated with **cancer** as antitumor targets
INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030964	A2	20010503	WO 2000-US29126	20001020
WO 2001030964	A3	20010809		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001013397	A5	20010508	AU 2001-13397		20001020
PRIORITY APPLN. INFO.:			US 1999-161232P	P	19991022
			US 2000-693783	A	20001019
			WO 2000-US29126	W	20001020

AB This invention relates to the discovery of nucleic acids associated with cell proliferation, neoplasia, cell transformation, malignant **tumor** formation and metastasis and uses therefor. The present invention provides a method for **cancer** diagnosing by detecting the overexpression or the underexpression of a **cancer**-associated mRNA in the tissue of interest, preferably in liver, breast, prostate, kidney and colon. In another aspect, the invention provides methods for arresting **cancer** and a method for identifying a modulators of **cancer** development.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heparin binding, gene for; nucleic acids and proteins associated with **cancer** as antitumor targets)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 15 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158474 CAPLUS
DOCUMENT NUMBER: 142:254569
TITLE: Derivatives of cyclic quinone that regulate gene expression for use in prevention or therapy of human diseases
INVENTOR(S): Padia, Janak K.; O'Brien, Sean; Lu, Jiemin; Pikul, Stanislaw
PATENT ASSIGNEE(S): Avalon Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016000	A1	20050224	WO 2004-US25038	20040803

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRIORITY APPLN. INFO.:		US 2003-492653P	P	20030805
OTHER SOURCE(S):	MARPAT 142:254569			

AB This invention relates to production of cyclic quinone derivs. for use in regulation of gene expression, as relates to prevention or therapy of

human diseases. Cyclic quinone synthesis schemes and structures are presented. With the goal of transcription regulation in diseased tissues, gene expression profile data is provided. The intended disease target for this invention is adenocarcinoma of the colon, however the invention claims application in numerous human diseases. Applications of the invention include production of cyclic quinone-based active ingredients in therapeutic agents.

IT **127464-60-2**, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(derivs. of cyclic quinone that regulate gene expression for use in prevention or therapy of human diseases)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 16 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:248644 CAPLUS
DOCUMENT NUMBER: 142:274057
TITLE: Sequences of human schizophrenia related genes and use for diagnosis, prognosis and therapy
INVENTOR(S): Liew, Choong-chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004241727	A1	20041202	US 2004-812731		20040330
US 2004014059	A1	20040122	US 2002-268730		20021009
US 2005191637	A1	20050901	US 2004-803737		20040318
US 2005196762	A1	20050908	US 2004-803759		20040318
US 2005196763	A1	20050908	US 2004-803857		20040318
US 2005196764	A1	20050908	US 2004-803858		20040318
US 2005208505	A1	20050922	US 2004-803648		20040318
US 2004241727	A1	20041202	US 2004-812731		20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P	19990106
			US 2000-477148	B1	20000104
			US 2002-268730	A2	20021009
			US 2003-601518	A2	20030620
			US 2004-802875	A2	20040312
			US 2004-812731	A	20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **385223-15-4**, GenBank AF011466
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(nucleotide sequence; sequences of human schizophrenia-related genes and use for diagnosis, prognosis and therapy)
RN 385223-15-4 CAPLUS
CN GenBank AF011466 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 17 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:287092 CAPLUS
DOCUMENT NUMBER: 136:384733
TITLE: Sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses
AUTHOR(S): Idzko, Marco; Panther, Elisabeth; Corinti, Silvia; Morelli, Anna; Ferrari, Davide; Herouy, Yared; Dichmann, Stefan; Mockenhaup, Maja; Gebicke-Haerter, Peter; Di Virgilio, Francesco; Girolomoni, Giampiero; Norgauer, Johannes
CORPORATE SOURCE: Department of Experimental Dermatology, Freiburg, Germany
SOURCE: FASEB Journal (2002), 16(6), 625-627, 10.1096/fj.01-0625fje
CODEN: FAJOEC; ISSN: 0892-6638
PUBLISHER: Federation of American Societies for Experimental Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Sphingosine 1-phosphate (S1P) is a potent extracellular lysolipid phosphoric acid mediator that is released after IgE-stimulation of mast cells. Here we investigated the biol. activity and intracellular signaling of S1P on human dendritic cells (DC), which are specialized antigen presenting cells with the ability to migrate into peripheral tissues and lymph nodes, as well as control the activation of naive T cells. We show that immature and mature DC express the mRNA for different S1P receptors, such as endothelial differentiation gene (**EDG**)-1, **EDG**-3, **EDG**-5, and **EDG**-6. In immature DC, S1P stimulated pertussis toxin-sensitive Ca2+ increase actin-polymerization and chemotaxis. These responses were lost by DC matured with lipopolysaccharide. In maturing DC, however, S1P inhibited the secretion of **tumor** necrosis factor-α and interleukin (IL)-12, whereas it enhanced secretion of IL-10. As a consequence, mature DC exposed to S1P showed a reduced and increased capacity to generate allogeneic Th1 and Th2 responses, resp. In summary, our study implicates that S1P might regulate the trafficking of DC and ultimately favor Th2 lymphocyte-dominated immunity.
IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sphingosine 1-phosphate induces chemotaxis of immature dendritic cells and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 18 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:394682 CAPLUS

DOCUMENT NUMBER: 142:445550
TITLE: Gene expression profiles for the diagnosis and prognosis of breast **cancer**
INVENTOR(S): Erlander, Mark; Ma, Xiao-Jun; Wang, Wei; Wittliff, James L.
PATENT ASSIGNEE(S): Arcturus Bioscience, Inc. University of Louisville, USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005095607	A1	20050505	US 2004-795092	20040305
WO 2005098037	A1	20051020	WO 2004-US6760	20040305
WO 2005098037	C1	20060209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1651772	A1	20060503	EP 2004-718019	20040305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-453006P P 20030307
WO 2004-US6760 W 20040305

AB The invention relates to the identification and use of gene expression profiles, or patterns, suitable for identification of breast **cancer** patient populations with different survival outcomes. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats, and may be used in the study and/or determination of the prognosis of a patient, including breast **cancer** survival.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(gene for, in breast **cancer** diagnosis; gene expression profiles for diagnosis and prognosis of breast **cancer**)
RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 19 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:807997 CAPLUS
DOCUMENT NUMBER: 140:126171
TITLE: Genes commonly upregulated by hypoxia in human breast **cancer** cells MCF-7 and MDA-MB-231
AUTHOR(S): Bando, Hiroko; Toi, Masakazu; Kitada, Kunio; Koike, Morio
CORPORATE SOURCE: Breast Cancer Research Group, Tokyo Metropolitan Cancer and Infectious Diseases Center, Bunkyo-ku, Tokyo, 113-0087, Japan
SOURCE: Biomedicine & Pharmacotherapy (2003), 57(8), 333-340

CODEN: BIPHEX; ISSN: 0753-3322
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Hypoxia is a stress that causes alterations in signal transduction and gene instability. In the **cancer** microenvironment, hypoxia plays a significant role in forming a **tumor** phenotype and **tumor** progression. We aimed to identify the genes upregulated by hypoxia in human breast **cancer** cell lines, a hormone-dependent MCF-7 and a hormone-independent MDA-MB-231, using microarray anal. These cells were exposed to two oxygen concns. such as 21% and 1% in a time-course. Out of 12,625 genes, 26 genes were identified as commonly upregulated in both MCF-7 and MDA-MB-231 cells. Some of these genes were already reported as hypoxia-related, but some of those were identified newly. These commonly upregulated genes between hormone-dependent and hormone-independent cells would be a clue to study hypoxia-related events and to explore the novel therapeutic targets in human breast **cancer**.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene commonly upregulated by hypoxia in human breast **cancer**)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 20 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:634161 CAPLUS
DOCUMENT NUMBER: 141:167758
TITLE: Sequences of apoptosis-associated protein kinases and G protein-coupled receptors, and use in **cancer** diagnosis, therapy, and drug screening
INVENTOR(S): Seery, Liam; Hayes, Ian; Murphy, Finbarr
PATENT ASSIGNEE(S): Eirx Therapeutics Limited, Ire.
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065959	A2	20040805	WO 2004-GB271	20040123
WO 2004065959	A3	20041125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004205785	A1	20040805	AU 2004-205785	20040123
CA 2513148	AA	20040805	CA 2004-2513148	20040123
EP 1588163	A2	20051026	EP 2004-704638	20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006518590	T2	20060817	JP 2006-500235	20040123
PRIORITY APPLN. INFO.:			GB 2003-1566 A	20030123
			US 2003-457533P P	20030325
			WO 2004-GB271 W	20040123

AB The present invention identifies a number of genes, "apoptosis-associated" genes, whose expression is correlated with an early stage in the regulation of apoptosis. The identification and role of these genes in

apoptosis is validated using model assays and by knocking down gene expression using RNAi and assessing the resultant phenotype for altered apoptosis progression. Accordingly, these genes represent new targets for therapeutic targets. Methods are provided for identifying agents that modulate the function of an apoptosis-associated polypeptide or expression of nucleic acids encoding the apoptosis-associated polypeptide, as well as detecting the presence of an apoptosis-associated polypeptide in a sample using hybridization-based levels of gene expression or antibody binding.

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequences of apoptosis-associated protein kinases and G protein-coupled receptors, and use in **cancer** diagnosis, therapy, and drug screening)

RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

L43 ANSWER 21 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:925904 CAPLUS
DOCUMENT NUMBER: 141:393465
TITLE: Genes showing altered expression in lung **cancer** and their products and their use in diagnosis and treatment
INVENTOR(S): Mennerich, Detlev; Bruemmendorf, Thomas; Heiden Castanos-Velez, Esmeralda; Hermann, Klaus; Kinnemann, Henrik; Li, Xinzhong; Roepcke, Stefan; Staub, Eike; Hinzmann, Bernd; Rosenthal, Andre; Pilarsky, Christian
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 1381 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10316701	A1	20041104	DE 2003-10316701	20030409
EP 1498424	A2	20050119	EP 2004-90140	20040408
EP 1498424	A3	20050525		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: DE 2003-10316701 A 20030409

AB Genes showing altered levels of expression in human bronchial carcinoma are identified for use in the diagnosis or treatment of the disease. Expression of the gene or presence of the gene product may be used as a diagnostic marker and either the gene or its product may be a target for antineoplastic drugs. Microarray anal. identified 489 genes showing altered patterns of expression in patients with lung adenocarcinoma or squamous cell carcinoma.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gene for, altered expression in bronchial carcinoma; genes showing altered expression in lung **cancer** and their products and their use in diagnosis and treatment)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:587551 CAPLUS
DOCUMENT NUMBER: 135:302740
TITLE: Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma
AUTHOR(S): Ammit, Alaina J.; Hastie, Annette T.; Edsall, Lisa C.; Hoffman, Rebecca K.; Amrani, Yassine; Krymskaya, Vera P.; Kane, Sibyl A.; Peters, Stephen P.; Penn, Raymond B.; Spiegel, Sarah; Panettieri, Reynold A., Jr.
CORPORATE SOURCE: Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
SOURCE: FASEB Journal (2001), 15(7), 1212-1214, 10.1096/fj.00-0742fje
CODEN: FAJOEC; ISSN: 0892-6638
PUBLISHER: Federation of American Societies for Experimental Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Asthma is characterized by airway inflammation, remodeling, and hyperresponsiveness to contractile stimuli that promote airway constriction and wheezing. Here we present evidence that sphingosine 1-phosphate (SPP) is a potentially important inflammatory mediator implicated in the pathogenesis of airway inflammation and asthma. SPP levels were elevated in the airways of asthmatic (but not control) subjects following segmental antigen challenge, and this increase was correlated with a concomitant increase in airway inflammation. Because human airway smooth muscle (ASM) cells expressed **EDG** receptors for SPP (**EDG**-1, -3, -5, and -6), we examined whether SPP may play a role in airway inflammation and remodeling, by affecting ASM cell growth, contraction, and cytokine secretion. SPP is mitogenic and augments EGF- and thrombin-induced DNA proliferation by increasing G1/S progression. SPP increased phosphoinositide turnover and intracellular calcium mobilization, the acute signaling events that affect ASM contraction. By modulating adenylate cyclase activity and cAMP accumulation, SPP had potent effects on cytokine secretion. Although SPP inhibited TNF-α-induced RANTES release, it induced substantial IL-6 secretion alone and augmented production of IL-6 induced by TNF-α. These studies are the first to associate SPP with airway inflammation and to identify SPP as an effective regulator of ASM growth, contraction and synthetic functions.
IT **7440-70-2**, Calcium, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transport; sphingosine 1-phosphate in **EDG** receptor-mediated modulating human airway smooth muscle cell growth, contraction and cAMP-dependent cytokine secretion promoting inflammation and airway remodeling in asthma in relation to)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:795460 CAPLUS

DOCUMENT NUMBER: 137:309424
TITLE: The influence of lysophosphatidic acid on the functions of human dendritic cells
AUTHOR(S): Panther, Elisabeth; Idzko, Marco; Corinti, Silvia; Ferrari, Davide; Herouy, Yared; Mockenhaupt, Maja; Dichmann, Stefan; Gebicke-Haerter, Peter; Di Virgilio, Francesco; Girolomoni, Giampiero; Norgauer, Johannes
CORPORATE SOURCE: Department of Experimental Dermatology, University of Freiburg, Freiburg, D-79104, Germany
SOURCE: Journal of Immunology (2002), 169(8), 4129-4135
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Lysophosphatidic acid (LPA) is a bioactive lipid mediator which is generated by secretory phospholipase A2. In this study, the authors studied the biol. activity of LPA on human dendritic cells (DCs), which are specialized APCs characterized by their ability to migrate into target sites and secondary lymphoid organs to process Ags and activate naive T cells. The authors show that immature and mature DCs express the mRNA for different LPA receptors such as endothelial differentiation gene (**EDG**)-2, **EDG**-4, and **EDG**-7. In immature DCs, LPA stimulated pertussis toxin-sensitive Ca2+ increase, actin polymerization, and chemotaxis. During the maturation process, DCs lost their ability to respond toward LPA with Ca2+ transients, actin polymerization, and chemotaxis. However, LPA inhibited in a pertussis toxin-insensitive manner the secretion of IL-12 and TNFα as well as enhanced secretion of IL-10 from mature DCs. Moreover, LPA did not affect the endocytic or phagocytic capacities and the surface phenotype of DCs, although it increased the allostimulatory function of mature DC and inhibited their capacity to induce Th1 differentiation. In summary, the authors' study implicates that LPA might regulate the trafficking, cytokine production, and T cell-activating functions of DCs.

IT **7440-70-2**, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(influence of lysophosphatidic acid on functions of human dendritic cells)
RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:612542 CAPLUS
DOCUMENT NUMBER: 143:114060
TITLE: Highly active lysophosphatidic acids and antibodies for disease diagnosis and therapy and drug screening
INVENTOR(S): Hayashi, Akio; Nakade, Shinji; Suzuki, Hidehiro
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005064332	A1	20050714	WO 2004-JP19241	20041222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2003-432844 A 20031226
JP 2004-224351 A 20040730

OTHER SOURCE(S): MARPAT 143:114060

AB The invention provides a method of screening a preventive and/or therapeutic substance for diseases in which LPA takes part. The compds. obtained by this screening method or with the use of relevant screening kit, their salts or solvates and prodrugs thereof would modulate the binding of highly active LPA with LPA receptor in human and other mammals, so that they can be used as a preventive and/or therapeutic agent for diseases in which LPA takes part, for example, urinary diseases, central diseases, inflammatory diseases, circulatory diseases, **cancer**, diabetes, immune system disorders and alimentary diseases.

IT **7440-70-2**, Calcium, biological studies
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(intracellular concentration; highly active lysophosphatidic acids and antibodies for drug screening and diagnosis and therapy of urinary, CNS, inflammatory, circulatory, immune and **neoplastic** disease)

RN 7440-70-2 CAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1291789 CAPLUS
DOCUMENT NUMBER: 144:46156
TITLE: Differential expression of molecules associated with acute stroke
INVENTOR(S): Baird, Alison E.; Moore, David F.; Goldin, Ehud
PATENT ASSIGNEE(S): United States Dept. of Health, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116268	A2	20051208	WO 2005-US18744	20050527

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006046259	A1	20060302	US 2005-155835	20050617
PRIORITY APPLN. INFO.:			US 2004-575279P	P 20040527
			WO 2005-US18744	A2 20050527

AB Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurol. recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)
(differential expression of mols. associated with acute stroke)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L43 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2006:21952 CAPLUS
DOCUMENT NUMBER:	144:485756
TITLE:	Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites
AUTHOR(S):	Sako, Akihiro; Kitayama, Joji; Shida, Dai; Suzuki, Rika; Sakai, Teruyuki; Ohta, Hideo; Nagawa, Hirokazu
CORPORATE SOURCE:	Department of Surgical Oncology, University of Tokyo, Japan
SOURCE:	Journal of Surgical Research (2006), 130(1), 94-101 CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER:	Elsevier
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Background: Lysophosphatidic acid (LPA) is a lipid mediator with multiple biol. activities that may affect the progression of various **cancers**. Malignant ascites contains high levels of LPA as well as vascular endothelial growth factor (VEGF). Although LPA receptors are widely expressed in normal as well as **cancer** cells, little is known about the effect of LPA on host cells. Therefore, we evaluated the effect of LPA specifically on peritoneal mesothelial cells (PMC), and assessed another aspect of LPA in **tumor** biol. mediated through the host cells. Materials and methods: The effect of LPA on the production of VEGF was evaluated by ELISA and northern blotting. Next, we quantified human- and mouse-VEGF sep. in ascitic fluid of nude mice inoculated i.p. with a human gastric **cancer**, MKN45, and thus evaluated the ratio of host-derived VEGF in malignant ascites. Results: Addition of 10 to 80 μM LPA enhanced VEGF production by PMC through gene activation. The effect was strongly inhibited by pre-treatment with PTX or Ki16425, indicating

that the effect was mainly dependent on the LPA1 signal. Of the VEGF in ascitic fluid at 3 wk after **tumor** inoculation, 12.8% was derived from mouse cells. At 6 wk, however, the ratio of host-derived VEGF was reduced to 5.0%, suggesting that the ratio of host-derived VEGF may be higher in the earlier phase. Conclusion: Because **tumor** growth is often associated with an increase of LPA concentration in ascites, stimulation of VEGF production in PMC might have an important role in the growth of **cancer** cells disseminated in the peritoneal cavity.

IT **127464-60-2**, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lysophosphatidic acid enhanced vascular endothelial growth factor production in human PMC and reduced mouse and human-derived VEGF in ascitic fluid of mouse model inoculated i.p. with human gastric **cancer** cell line MKN45)

RN 127464-60-2 CAPLUS
CN Vascular endothelial growth factor (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:112850 CAPLUS
DOCUMENT NUMBER: 142:153469
TITLE: Gene expression profiles and biomarkers for the detection of lung disease-related and other disease-related gene transcripts in blood
INVENTOR(S): Liew, Choong-chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 47
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241728	A1	20041202	US 2004-812764	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2005191637	A1	20050901	US 2004-803737	20040318
US 2005196762	A1	20050908	US 2004-803759	20040318
US 2005196763	A1	20050908	US 2004-803857	20040318
US 2005196764	A1	20050908	US 2004-803858	20040318
US 2005208505	A1	20050922	US 2004-803648	20040318
US 2004241728	A1	20041202	US 2004-812764	20040330
PRIORITY APPLN. INFO.:			US 1999-115125P	P 19990106
			US 2000-477148	B1 20000104
			US 2002-268730	A2 20021009
			US 2003-601518	A2 20030620
			US 2004-802875	A2 20040312
			US 2004-812764	A 20040330

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially expressed gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder **cancer**, rheumatoid arthritis, osteoarthritis, liver **cancer**, schizophrenia, Chagas

disease, asthma, and manic depression syndrome. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **385223-15-4**, GenBank AF011466
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

E1	1	108-31-6/BI
E2	1	108-38-3/BI
E3	1	119-80-2/BI
E4	1	1226-42-2/BI
E5	1	127464-60-2/BI
E6	1	306764-68-1/BI
E7	1	312501-62-5/BI
E8	1	331945-22-3/BI
E9	1	353771-45-6/BI
E10	1	40622-01-3/BI
E11	1	4506-71-2/BI
E12	1	5242-26-2/BI
E13	1	569656-05-9/BI
E14	1	569656-06-0/BI
E15	1	569656-29-7/BI
E16	1	60-92-4/BI
E17	1	619-05-6/BI
E18	1	64900-65-8/BI
E19	1	66085-59-4/BI
E20	1	7440-70-2/BI
E21	1	76293-13-5/BI
E22	1	7741-54-0/BI
E23	1	82799-44-8/BI
E24	1	91-56-5/BI
E25	1	108-31-6/BI
E26	1	108-38-3/BI
E27	1	119-80-2/BI
E28	1	1226-42-2/BI
E29	1	127464-60-2/BI
E30	1	306764-68-1/BI
E31	1	312501-62-5/BI
E32	1	331945-22-3/BI
E33	1	353771-45-6/BI
E34	1	40622-01-3/BI
E35	1	4506-71-2/BI
E36	1	5242-26-2/BI
E37	1	569656-05-9/BI
E38	1	569656-06-0/BI
E39	1	569656-29-7/BI
E40	1	60-92-4/BI
E41	1	619-05-6/BI
E42	1	64900-65-8/BI
E43	1	66085-59-4/BI
E44	1	7440-70-2/BI
E45	1	76293-13-5/BI
E46	1	7741-54-0/BI
E47	1	82799-44-8/BI
E48	1	91-56-5/BI
E49	1	100-65-2/BI
E50	1	107235-67-6/BI
E51	1	108-31-6/BI
E52	1	108-38-3/BI
E53	1	112612-58-5/BI
E54	1	113054-02-7/BI
E55	1	120-72-9/BI
E56	1	1226-42-2/BI
E57	1	123-11-5/BI
E58	1	127464-60-2/BI
E59	1	13100-05-5/BI
E60	1	13380-67-1/BI
E61	1	136382-28-0/BI
E62	1	140-75-0/BI

E63	1	1468-83-3/BI
E64	1	1476-23-9/BI
E65	1	149246-80-0/BI
E66	1	149246-86-6/BI
E67	1	1572-10-7/BI
E68	1	171286-07-0/BI
E69	1	173275-26-8/BI
E70	1	177360-28-0/BI
E71	1	182762-25-0/BI
E72	1	19541-95-8/BI
E73	1	208519-10-2/BI
E74	1	208519-15-7/BI
E75	1	218763-60-1/BI
E76	1	23448-86-4/BI
E77	1	23821-37-6/BI
E78	1	259476-69-2/BI
E79	1	262400-57-7/BI
E80	1	2642-63-9/BI
E81	1	26993-30-6/BI
E82	1	292076-38-1/BI
E83	1	302-01-2/BI
E84	1	304650-31-5/BI
E85	1	306764-68-1/BI
E86	1	309282-30-2/BI
E87	1	311773-65-6/BI
E88	1	311799-07-2/BI
E89	1	312501-62-5/BI
E90	1	312519-16-7/BI
E91	1	312594-43-7/BI
E92	1	321679-76-9/BI
E93	1	322662-05-5/BI
E94	1	327167-87-3/BI
E95	1	329069-72-9/BI
E96	1	329350-38-1/BI
E97	1	330630-42-7/BI
E98	1	331274-84-1/BI
E99	1	331945-22-3/BI
E100	1	332161-39-4/BI
E101	1	334498-72-5/BI
E102	1	337349-59-4/BI
E103	1	337469-26-8/BI
E104	1	337498-14-3/BI
E105	1	342384-25-2/BI
E106	1	346699-98-7/BI
E107	1	353253-35-7/BI
E108	1	353273-74-2/BI
E109	1	353463-50-0/BI
E110	1	353771-45-6/BI
E111	1	353793-15-4/BI
E112	1	355000-90-7/BI
E113	1	363-58-6/BI
E114	1	364051-15-0/BI
E115	1	36817-57-9/BI
E116	1	372-31-6/BI
E117	1	383164-60-1/BI
E118	1	384729-36-6/BI
E119	1	385223-15-4/BI
E120	1	389079-78-1/BI
E121	1	390105-18-7/BI
E122	1	390174-36-4/BI
E123	1	390523-03-2/BI
E124	1	39151-19-4/BI
E125	1	392101-34-7/BI

E126	1	400064-03-1/BI
E127	1	406-00-8/BI
E128	1	40622-01-3/BI
E129	1	43071-45-0/BI
E130	1	434-75-3/BI
E131	1	4506-71-2/BI
E132	1	473390-98-6/BI
E133	1	49843-94-9/BI
E134	1	50-30-6/BI
E135	1	50-45-3/BI
E136	1	502132-61-8/BI
E137	1	5242-26-2/BI
E138	1	533-18-6/BI
E139	1	5351-85-9/BI
E140	1	5351-91-7/BI
E141	1	5467-70-9/BI
E142	1	556-90-1/BI
E143	1	569655-94-3/BI
E144	1	569655-95-4/BI
E145	1	569655-96-5/BI
E146	1	569655-97-6/BI
E147	1	569655-98-7/BI
E148	1	569655-99-8/BI
E149	1	569656-00-4/BI
E150	1	569656-01-5/BI
E151	1	569656-02-6/BI
E152	1	569656-03-7/BI
E153	1	569656-04-8/BI
E154	1	569656-05-9/BI
E155	1	569656-06-0/BI
E156	1	569656-07-1/BI
E157	1	569656-08-2/BI
E158	1	569656-09-3/BI
E159	1	569656-10-6/BI
E160	1	569656-11-7/BI
E161	1	569656-12-8/BI
E162	1	569656-13-9/BI
E163	1	569656-14-0/BI
E164	1	569656-15-1/BI
E165	1	569656-16-2/BI
E166	1	569656-17-3/BI
E167	1	569656-18-4/BI
E168	1	569656-19-5/BI
E169	1	569656-20-8/BI
E170	1	569656-21-9/BI
E171	1	569656-22-0/BI
E172	1	569656-23-1/BI
E173	1	569656-24-2/BI
E174	1	569656-25-3/BI
E175	1	569656-26-4/BI
E176	1	569656-27-5/BI
E177	1	569656-28-6/BI
E178	1	569656-29-7/BI
E179	1	60-92-4/BI
E180	1	619-05-6/BI
E181	1	619-41-0/BI
E182	1	6292-74-6/BI
E183	1	64900-65-8/BI
E184	1	6629-60-3/BI
E185	1	70-11-1/BI
E186	1	72411-52-0/BI
E187	1	7420-34-0/BI
E188	1	7440-70-2/BI

E189	1	76293-13-5/BI
E190	1	7741-53-9/BI
E191	1	7741-54-0/BI
E192	1	79-19-6/BI
E193	1	82799-44-8/BI
E194	1	82799-45-9/BI
E195	1	829-20-9/BI
E196	1	83-38-5/BI
E197	1	86358-85-2/BI
E198	1	89570-85-4/BI
E199	1	90212-73-0/BI
E200	1	91-56-5/BI
E201	1	91912-53-7/BI
E202	1	93-17-4/BI
E203	1	93-55-0/BI
E204	1	94835-69-5/BI
E205	1	96799-03-0/BI
E206	1	96799-04-1/BI
E207	1	98-59-9/BI
E208	1	98-88-4/BI
E209	1	98-95-3/BI
E210	1	108-31-6/BI
E211	1	108-38-3/BI
E212	1	119-80-2/BI
E213	1	1226-42-2/BI
E214	1	127464-60-2/BI
E215	1	306764-68-1/BI
E216	1	312501-62-5/BI
E217	1	331945-22-3/BI
E218	1	353771-45-6/BI
E219	1	40622-01-3/BI
E220	1	4506-71-2/BI
E221	1	5242-26-2/BI
E222	1	569656-05-9/BI
E223	1	569656-06-0/BI
E224	1	569656-29-7/BI
E225	1	60-92-4/BI
E226	1	619-05-6/BI
E227	1	64900-65-8/BI
E228	1	66085-59-4/BI
E229	1	7440-70-2/BI
E230	1	76293-13-5/BI
E231	1	7741-54-0/BI
E232	1	82799-44-8/BI
E233	1	91-56-5/BI

Connecting via Winsock to STN

Connecting via Winsock to STN

Connecting via Winsock to STN

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 5	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6	MAY 11	KOREAPAT updates resume
NEWS 7	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 8	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 10	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 11	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 14	JUl 14	FSTA enhanced with Japanese patents
NEWS 15	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 16	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 17	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 18	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:33:46 ON 31 AUG 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.52	2.52

FILE 'REGISTRY' ENTERED AT 19:41:10 ON 31 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0
DICTIONARY FILE UPDATES: 30 AUG 2006 HIGHEST RN 905475-39-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10760002.str

L1 STRUCTURE UPLOADED

=> s sss l1 full
FULL SEARCH INITIATED 19:41:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

```
L2             7 SEA SSS FUL L1

=> file caplus biosis embase uspatful
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.94     169.46

FILE 'CAPLUS' ENTERED AT 19:41:42 ON 31 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 19:41:42 ON 31 AUG 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 19:41:42 ON 31 AUG 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 19:41:42 ON 31 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
L3             5 L2

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4             3 DUP REM L3 (2 DUPLICATES REMOVED)

=> d ibib abs it hitstr 1-3

L4   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN  DUPLICATE 1
ACCESSION NUMBER:         2005:1242755  CAPLUS
DOCUMENT NUMBER:          143:472565
TITLE:                    Methods of treating conditions associated with an
                          Edg-7 receptor
INVENTOR(S):              Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet
                          V.; Gluchowski, Charles
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S.
                          Ser. No. 352,579.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   4
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2005261298         A1    20051124    US 2003-390428           20030314
     WO 2003062392         A2    20030731    WO 2003-US1881           20030121
     WO 2003062392         A3    20050120
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                       US 2002-350446P     P  20020118
```

WO 2003-US1881	A1	20030121
US 2003-352579	B2	20030127
US 2002-350445P	P	20020118
US 2002-350447P	P	20020118
US 2002-350448P	P	20020118

OTHER SOURCE(S): MARPAT 143:472565

AB In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject.

IT Animal cell line
(A431; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Dopamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(D2(long); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG (endothelial differentiation gene); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-3 (endothelial differentiation gene 3); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-4 (endothelial differentiation gene 4); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-5 (endothelial differentiation gene 5); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-6 (endothelial differentiation gene 6); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-7 (endothelial differentiation gene 7); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-8 (endothelial differentiation gene 8); Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Angiogenesis
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antitumor agents
Apoptosis

Asthma
Cardiovascular agents
Cardiovascular system, disease
Cell migration
Cell proliferation
Combination chemotherapy
Cytotoxic agents
Fibroblast
Human
Inflammation
Ischemia
Kidney, neoplasm
Lung, disease
Lung, neoplasm
Mammary gland, neoplasm
Myoblast
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm
Platelet (blood)
Platelet activation
Prostate gland, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Wound healing
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Muscarinic receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line
(HT-1080; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line
(HTC; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line
(HUVEC; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Histamine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(H1; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Calcium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(L-type; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line
(MDA-MB-231; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Animal cell line
(OV202, CAOV-3, MDA-MB-453; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT Respiratory distress syndrome
(adult; Edg-7 modulators for treating conditions associated with Edg-7

receptor)
IT Antiarteriosclerotics
(antiatherosclerotics; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Atherosclerosis
(atherogenesis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Immune system
(autoimmune response; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Biological transport
(calcium; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell proliferation stimulated by; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Carcinoma
Pheochromocytoma
(cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Uterus, neoplasm
(cervix; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Intestine, neoplasm
(colon; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Intestine, neoplasm
(colorectal; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Eye
(cornea, transcorneal freezing; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Burn
(cutaneous; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Uterus, neoplasm
(endometrium; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Epithelium
(epithelial cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Sarcoma
(fibrosarcoma, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Carcinoma
(hepatocellular, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Liver, neoplasm
(hepatoma, cell; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Neoplasm
(invasiveness; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Neoplasm
(metastasis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Ovary
(ovarian cell; Edg-7 modulators for treating conditions associated with

Edg-7 receptor)
IT Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymerization; Edg-7 modulators for treating conditions associated with Edg-7
receptor)
IT Intestine, neoplasm
(small; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Interleukin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 5-HT receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type 5-HT1; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type AT2; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Endothelin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type ETA; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α1; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α2; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(β-; Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 60-92-4, CAMP 127464-60-2, VEGF
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 40622-01-3P, 2,3-Bis(4-Methoxyphenyl)quinoxaline-6-carboxylic acid
66085-59-4P 306764-68-1P 312501-62-5P **331945-22-3P**
353771-45-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions
108-38-3, 1,3-Dimethylbenzene, reactions 119-80-2 619-05-6,
3,4-Diaminobenzoic acid 1226-42-2, 4,4'-Dimethoxybenzil 4506-71-2,
Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[B]thiophene-3-carboxylate
5242-26-2 64900-65-8, 2-Chlorobenzenesulfonyl isocyanate 82799-44-8
569656-05-9 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 7741-54-0P 76293-13-5P, 2,4-Dimethylthioxanthen-9-one 569656-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)
IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(transport; Edg-7 modulators for treating conditions associated with Edg-7 receptor)

IT **331945-22-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with Edg-7 receptor)
RN 331945-22-3 CAPLUS
CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:703129 CAPLUS
DOCUMENT NUMBER: 141:218996
TITLE: Methods using Edg-7 modulators for treating conditions associated with an Edg-7 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet V.; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004167192	A1	20040826	US 2004-760002		20040116
PRIORITY APPLN. INFO.:			US 2003-440321P	P	20030116
			US 2003-454881P	P	20030313

OTHER SOURCE(S): MARPAT 141:218996
AB The invention provides a method for modulating an Edg-7 receptor mediated biol. activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor-mediated biol. activity. The invention also provides a method for modulating an Edg-7 receptor-mediated biol. activity in a subject. A therapeutically effective amount of a modulator of the Edg-7 receptor is administered to the subject. Preparation of e.g. 4-Bromo-2-[2-(4-chlorophenylamino)-4-oxothiazolidin-5-ylidenemethyl]phenoxyacetic acid is described.
IT Animal cell line
(A431; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Animal cell line
(CAOV-3; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG (endothelial differentiation gene); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg-7 modulators for

treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-3 (endothelial differentiation gene 3); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-4 (endothelial differentiation gene 4); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-5 (endothelial differentiation gene 5); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-6 (endothelial differentiation gene 6); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-7 (endothelial differentiation gene 7); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-8 (endothelial differentiation gene 8); Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Angiogenesis
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antitumor agents
Apoptosis
Asthma
Cardiovascular agents
Cardiovascular system, disease
Cell migration
Cell proliferation
Combination chemotherapy
Cytotoxic agents
Fibroblast
Human
Inflammation
Ischemia
Kidney, neoplasm
Lung, disease
Lung, neoplasm
Mammary gland, neoplasm
Myoblast
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm
Platelet (blood)
Platelet activation
Platelet activation
Prostate gland, neoplasm
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Wound healing

(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(HT-1080; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(HTC; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(HUVEC; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(MDA-MB-231; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(MDA-MB-453; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Animal cell line
(OV202; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Respiratory distress syndrome
(adult; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Antiarteriosclerotics
(antiatherosclerotics; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Atherosclerosis
(atherogenesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Immune system
(autoimmune response; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell proliferation stimulated by; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Carcinoma
Pheochromocytoma
(cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Uterus, neoplasm
(cervix; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Intestine, neoplasm
(colon; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Intestine, neoplasm
(colorectal; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Eye
(cornea, transcorneal freezing; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Burn
(cutaneous; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT Uterus, neoplasm
(endometrium; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Epithelium
(epithelial cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Sarcoma
(fibrosarcoma, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Carcinoma
(hepatocellular, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Liver, neoplasm
(hepatoma, cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Neoplasm
(invasiveness; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Ovary
(ovarian cell; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymerization; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Intestine, neoplasm
(small; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Epithelium
(surface epithelial cell injury; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT Interleukin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT 26993-30-6, Sphingosine-1-phosphate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT 312501-62-5P **331945-22-3P** 353771-45-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT 49581-16-0 333772-21-7 352444-98-5 352683-56-8 352694-02-1 744198-30-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT 91-56-5, 1H-Indole-2,3-dione 108-31-6, Maleic anhydride, reactions 5242-26-2 569656-05-9 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)
IT 60-92-4, Cyclic AMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation, inhibition; Edg-7 modulators for treating conditions

associated with an Edg-7 receptor)

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

IT **331945-22-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg-7 modulators for treating conditions associated with an Edg-7 receptor)

RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS

DOCUMENT NUMBER: 139:143997

TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions

INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles

PATENT ASSIGNEE(S): Ceretek LLC, USA

SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	AA	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005519915	T2	20050707	JP 2003-562260		20030121
US 2005261298	A1	20051124	US 2003-390428		20030314
PRIORITY APPLN. INFO.:			US 2002-350445P	P	20020118
			US 2002-350446P	P	20020118
			US 2002-350447P	P	20020118
			US 2002-350448P	P	20020118
			WO 2003-US1881	W	20030121
			US 2003-352579	B2	20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g. 4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

IT Animal cell line
(A431; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(CAOV-3; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Inflammation
(Crohn's disease; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Intestine, disease
(Crohn's; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-1 (endothelial differentiation gene 1); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-3 (endothelial differentiation gene 3); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-5 (endothelial differentiation gene 5); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-6 (endothelial differentiation gene 6); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT G protein-coupled receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-8 (endothelial differentiation gene 8); Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Angiogenesis
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antiasthmatics
Antimigraine agents

Antirheumatic agents
Antitumor agents
Apoptosis
Asthma
Atherosclerosis
Behcet's syndrome
Cardiovascular agents
Cardiovascular system, disease
Cell migration
Cell proliferation
Cytotoxic agents
Fibroblast
Gastrointestinal agents
Human
Inflammation
Ischemia
Kidney, neoplasm
Lung, disease
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Neuron
Ovary, neoplasm
Pancreas, neoplasm
Peritoneum, neoplasm
Platelet (blood)
Platelet activation
Platelet activation
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Stomach, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
Vasoconstriction
Vasodilators
Wound
Wound healing promoters
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Carbohydrates, biological studies
Nucleic acids
Organic compounds, biological studies
Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-4; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg-7; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Edg; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(HT-1080; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Animal cell line
(HTC; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Animal cell line
(HUVEC; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Chemotaxis
(LPA-stimulated; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Animal cell line
(MDA-MB-231; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Animal cell line
(MDA-MB-453; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Animal cell line
(OV202; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Animal cell line
(SKOV3; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Respiratory distress syndrome
(adult; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Antiarteriosclerotics
(antiatherosclerotics; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Anemia (disease)
Autoimmune disease
(autoimmune hemolytic anemia; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Immunity
(autoimmunity; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Lysophosphatidic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cell proliferation stimulated by; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Carcinoma
Myoblast
Pheochromocytoma
(cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Artery
(cerebral, vasoconstriction; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Uterus, neoplasm
(cervix; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Resolution (separation)
(chromatog.; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Infection
(chronic active hepatitis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Inflammation
Kidney, disease
(chronic glomerulonephritis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Temperature effects, biological
(cold, transcomeal freezing; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Intestine, neoplasm

(colon; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Intestine, neoplasm
(colorectal; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Burn
(cutaneous; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Meninges
(disease, subarachnoid hemorrhage; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Uterus, neoplasm
(endometrium; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Blood vessel
(endothelium; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Epithelium
(epithelial cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Carcinoma
(epithelioid; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Sarcoma
(fibrosarcoma, cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Carcinoma
(hepatocellular; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Liver, neoplasm
(hepatoma; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Phosphatidylinositols
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydrolysis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(level of; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lysophosphatidic acid; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Neoplasm
(metastasis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Headache
(migraine; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Kidney, disease
(non-glomerular nephrosis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Blood vessel, disease
(occlusion; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Egg
(oocyte, Xenopus laevis; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Xenopus laevis
(oocyte; Edg receptor modulators for treatment of Edg receptor-associated conditions)
IT Ovary

(ovarian cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Actins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymerization; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Intestine, neoplasm
(small; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Blood vessel, disease
(spasm; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Brain, disease
(stroke; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Hemorrhage
(subarachnoid; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Injury
(surface epithelial cell; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Interleukin 8
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Lupus erythematosus
(systemic; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Purpura (disease)
(thrombocytopenic, chronic; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Inflammation
Intestine, disease
(ulcerative colitis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Endothelium
(vascular; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT Hepatitis
(viral, chronic active; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 182762-25-0, GenBank X83864 218763-60-1, GenBank AJ000479 259476-69-2, GenBank AF233092 262400-57-7, GenBank AF233090 384729-36-6, GenBank U78192 385223-15-4, GenBank AF011466 390105-18-7, GenBank AF034780 390174-36-4, GenBank AF233365 390523-03-2, GenBank AF317676 392101-34-7, GenBank AF127138
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 473390-98-6
RL: FMU (Formation, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 353273-74-2P 569655-94-3P 569655-95-4P 569655-96-5P 569656-23-1P 569656-24-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated

conditions)

IT 94835-69-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 7741-53-9P 40622-01-3P 173275-26-8P 304650-31-5P 311799-07-2P
312501-62-5P 312519-16-7P **331945-22-3P** 334498-72-5P
342384-25-2P 353253-35-7P 353771-45-6P 355000-90-7P 569656-08-2P
569656-09-3P 569656-10-6P 569656-11-7P 569656-12-8P 569656-13-9P
569656-14-0P 569656-15-1P 569656-16-2P 569656-17-3P 569656-18-4P
569656-19-5P 569656-20-8P 569656-21-9P 569656-25-3P 569656-26-4P
569656-27-5P 569656-29-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 49843-94-9 90212-73-0 107235-67-6 136382-28-0 171286-07-0
177360-28-0 292076-38-1 306764-68-1 309282-30-2 311773-65-6
312594-43-7 321679-76-9 322662-05-5 327167-87-3 329350-38-1
330630-42-7 331274-84-1 332161-39-4 337349-59-4 337469-26-8
337498-14-3 346699-98-7 353463-50-0 353793-15-4 364051-15-0
383164-60-1 389079-78-1 400064-03-1 569655-97-6 569655-98-7
569656-22-0 569656-28-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 50-30-6, 2,6-Dichlorobenzoic acid 50-45-3, 2,3-Dichlorobenzoic acid
70-11-1, 2-Bromoacetophenone 79-19-6, Thiosemicarbazide 83-38-5,
2,6-Dichlorobenzaldehyde 91-56-5, 1H-Indole-2,3-dione 93-17-4,
3,4-Dimethoxyphenylacetonitrile 93-55-0, Propiophenone 98-59-9,
p-Toluenesulfonyl chloride 98-88-4, Benzoyl chloride 98-95-3,
Nitrobenzene, reactions 100-65-2, N-Phenylhydroxylamine 108-31-6,
Maleic anhydride, reactions 108-38-3, 1,3-Dimethylbenzene, reactions
120-72-9, Indole, reactions 123-11-5, p-Anisaldehyde, reactions
140-75-0, 4-Fluorobenzylamine 302-01-2, Hydrazine, reactions 363-58-6
372-31-6, Ethyl 4,4,4-trifluoroacetoacetate 406-00-8,
4-Fluorophenylhydroxylamine 434-75-3, 2-Chloro-6-fluorobenzoic acid
533-18-6, o-Tolyl acetate 556-90-1, Pseudothiohydantoin 619-05-6,
3,4-Diaminobenzoic acid 619-41-0, 2-Bromo-4'-methylacetophenone
829-20-9 1226-42-2, 4,4'-Dimethoxybenzil 1468-83-3, 3-Acetylthiophene
1476-23-9, Allyl isocyanate 1572-10-7 2642-63-9, 3',4'-
Dichloroacetophenone 4506-71-2 5242-26-2 5351-85-9 6629-60-3,
Ethylhydrazine oxalate 13100-05-5 13380-67-1 19541-95-8 23448-86-4
23821-37-6 36817-57-9 39151-19-4 64900-65-8, 2-Chlorobenzenesulfonyl
isocyanate 72411-52-0 82799-44-8 89570-85-4 96799-03-0
96799-04-1 569656-04-8 569656-05-9 569656-06-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 5351-91-7P 5467-70-9P 6292-74-6P 7420-34-0P 7741-54-0P
43071-45-0P 76293-13-5P 82799-45-9P 86358-85-2P 91912-53-7P
112612-58-5P 113054-02-7P 149246-80-0P 149246-86-6P 208519-10-2P
208519-15-7P 329069-72-9P 502132-61-8P 569655-99-8P 569656-00-4P
569656-01-5P 569656-02-6P 569656-03-7P 569656-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 26993-30-6, Sphingosine-1-phosphate

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(calcium mobilization stimulated by; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 60-92-4, Cyclic AMP
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation inhibition; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 7440-70-2, Calcium, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mobilization; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis; Edg receptor modulators for treatment of Edg receptor-associated conditions)

IT **331945-22-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Edg receptor modulators for treatment of Edg receptor-associated conditions)

RN 331945-22-3 CAPLUS

CN Benzenesulfonamide, N-[5-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)-4,5-dihydro-4-oxo-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)